~~Securities registered pursuant to Section 12(g) of the Act:~~ ~~Subordinate Voting Shares, no par value~~

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November 8, 2021,~~May 5, 2022, the registrant had ~~125,511,305~~135,001,544 Subordinate Voting Shares and ~~54,919,596~~49,217,899 Multiple Voting Shares (on an as converted basis), outstanding.

This Quarterly Report on Form 10-Q contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words. Any statements contained in this Quarterly Report on Form 10-Q that are not statements of historical facts may be deemed to be forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, results of operations and future growth prospects. The forward-looking statements contained herein are based on certain key expectations and assumptions, including, but not limited to, with respect to expectations and assumptions concerning receipt and/or maintenance of required licenses and third party consents and the success of our operations, are based on estimates prepared by us using data from publicly available governmental sources, as well as from market research and industry analysis, and on assumptions based on data and knowledge of this industry that we believe to be reasonable. These forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and discussed elsewhere in this Quarterly Report on Form 10-Q and in “Part I, Item 1A – Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this Quarterly Report on Form 10-Q.

The accompanying notes are an integral part of these ~~unaudited interim~~ condensed consolidated financial statements.

~~Unaudited Interim~~ Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income

The accompanying notes are an integral part of these ~~unaudited interim~~ condensed consolidated financial statements.

~~Unaudited Interim~~ Condensed Consolidated Statements of Changes in Shareholders’ Equity

The accompanying notes are an integral part of these ~~unaudited interim~~ condensed consolidated financial statements.

~~Unaudited Interim~~ Condensed Consolidated Statements of ~~Changes in Shareholders’ Equity~~Cash Flows

The accompanying notes are an integral part of these ~~unaudited interim~~ condensed consolidated financial statements.

~~The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.~~

NOTE 2. BASIS OF PRESENTATION

Principles of consolidation

The accompanying ~~unaudited~~ condensed consolidated financial statements include the financial position and operations of ~~the Company have been~~Trulieve Cannabis Corp. and its subsidiaries. The condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” ~~or "GAAP"~~) for interim financial information and include the ~~rules~~assets, liabilities, revenue and ~~regulations~~expenses of all wholly-owned subsidiaries and variable interest entities for which we have determined that we are the ~~Securities and Exchange Commission (the “SEC”).~~

~~The accompanying unaudited~~primary beneficiary. Outside shareholders' interests in subsidiaries are shown on the condensed consolidated financial statements ~~contain all normal~~as non-controlling interests. Material intercompany balances and ~~recurring adjustments necessary to state fairly~~transactions are eliminated in consolidation. In our opinion, the condensed consolidated financial ~~condition, results of operations, comprehensive income, statement of shareholders’ equity, and cash flows of the Company for the interim periods presented. Except as otherwise disclosed,~~statements include all ~~such~~ adjustments ~~consist only of those~~ of a normal recurring ~~nature. Operating~~nature necessary to present fairly our financial position as of March 31, 2022, and the results of our operations and cash flows for the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 and March 31, 2021. The results of our operations for the three months ended March 31, 2022 are not necessarily indicative of the results ~~that may~~to be expected for the ~~current year ending December 31, 2021.~~ full 2022 fiscal year.

A variable interest entity (“VIE”) is a legal entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support, is structured such that equity investors lack the ability to make significant decisions relating to the entity’s operations through voting rights, or do not substantively participate in the gains and losses of the entity. Upon inception of a contractual agreement, the Company performs an assessment to determine whether the arrangement contains a variable interest in a legal entity and whether that legal entity is a VIE. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE entity that could potentially be significant to the VIE. Where the Company concludes it is the primary beneficiary of a VIE, the Company consolidates the accounts of that VIE. When the Company is not the primary beneficiary, the VIE is accounted for using the equity method and is included in equity method investments on the consolidated balance sheets.

The Company regularly reviews and reconsiders previous conclusions regarding whether it is the primary beneficiary of a VIE in accordance with FASB ASC 810. The Company also reviews and reconsiders previous conclusions regarding whether the Company holds a variable interest in a potential VIE, the status of an entity as a VIE, and whether the Company is required to consolidate such a VIE in the consolidated financial statements when a change occurs.

The financial data presented herein should be read in conjunction with the audited consolidated financial statements and accompanying notes as of and for the ~~years~~year ended December 31, ~~2020 and 2019 (“2020 audited consolidated financial statements”).~~

~~The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the~~2021, as reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC and the instructions to Form 10-Q.

~~Revision of Previously Issued Financial Statements~~

During the quarter ended September 30, 2021, the Company identified an error in its accounting for leases which was due to the lack of a complete lease population and the conclusions reached for the commencement date for leases not aligning with the possession date of

the associated right of use asset. This resulted in an understatement of the associated right of use assets and the associated lease liabilities. The Company also identified a misstatement related to the accounting for asset acquisitions that were consummated during the three months ended June 30, 2021, which was due to the Company initially valuing the equity consideration transferred using the contract value whereas the fair value as of the closing date should have been used. This resulted in an understatement of intangible assets, an understatement of the associated deferred tax liabilities and an understatement of additional paid-in-capital. Additionally, the Company identified assets not likely to be converted within a year were classified as prepaid and other current assets, rather than other assets. The Company evaluated the misstatements and concluded that the misstatements were not material, either individually or in the ~~aggregate, to its current or previously issued consolidated financial statements.~~

~~To correct the immaterial misstatements, during the quarter ended September 30,~~ 2021 the Company elected to revise its previously issued interim unaudited condensed consolidated balance sheet as of June 30, 2021 and March 31, 2021 as well as the previously issued 2020 condensed consolidated balance sheet. The revision of the historical interim unaudited condensed consolidated balance sheet includes the correction of these immaterial misstatements as well as other previously identified balance sheet misclassifications. Accordingly, the accompanying interim unaudited condensed consolidated balance sheet and relevant footnotes in this QuarterlyAnnual Report on Form 10-Q as well as the 2020 condensed consolidated balance sheet have been revised to correct for such immaterial misstatements. The Company will present the revision of its previously issued interim unaudited condensed consolidated balance sheet as of March 31, 2021 and June 30, 2021, in connection with the future filing of its Quarterly Reports on Form 10-Q. The impact of the lease entries recorded as of June 30, 2021.10-K.

~~The impact of the revision on the Company’s interim unaudited condensed consolidated balance sheet as of June 30, 2021 is reflected in the following table:~~

Balance Sheet as of June 30, 2021 (unaudited)

As Previously Reported

Adjustment

As Revised

Prepaid expenses and other current assets

$
28,313

$
(4,249
)

$
24,064

Total current assets

442,090

(4,249
)

437,841

Property and equipment, net

427,666

258

427,924

Right of use assets - operating, net

31,254

8,768

40,022

Right of use assets - finance, net

41,521

6,371

47,892

Intangible assets, net

123,106

(621
)

122,485

Other assets

9,547

4,246

13,793

Total assets

1,146,307

14,773

1,161,080

Operating lease liabilities, current portion

3,583

432

4,015

Finance lease liabilities, current portion

4,723

281

5,004

Total current liabilities

76,738

713

77,451

Operating lease liabilities

29,381

8,396

37,777

Finance lease liabilities

39,694

5,822

45,516

Deferred tax liability

29,845

(2,213
)

27,632

Total liabilities

390,072

12,718

402,790

Additional paid-in-capital

522,898

2,055

524,953

Total shareholders equity

$
756,235

$
2,055

$
758,290

Balance Sheet as of March 31, 2021 (unaudited)

As Previously Reported

Adjustment

As Revised

Prepaid expenses and other current assets

$
25,180

$
(3,728
)

$
21,452

Total current assets

294,157

(3,728
)

290,429

Right of use assets - operating, net

30,051

2,830

32,881

Right of use assets - finance, net

38,380

1,838

40,218

Other assets

7,549

3,693

11,242

Total assets

897,455

4,633

902,088

Operating lease liabilities, current portion

3,324

173

3,497

Finance lease liabilities, current portion

4,344

70

4,414

Total current liabilities

100,900

243

101,143

Operating lease liabilities

28,326

2,581

30,907

Finance lease liabilities

36,294

1,809

38,103

Total liabilities

$
411,871

$
4,633

$
416,504

Balance Sheet as of December 31, 2020

As Previously Reported

Adjustment

As Revised

Prepaid expenses and other current assets

$
19,815

$
(3,696
)

$
16,119

Total current assets

265,148

(3,696
)

261,452

Right of use assets - operating, net

28,171

1,905

30,076

Other assets

3,944

3,584

7,528

Total assets

816,112

1,793

817,905

Operating lease liabilities, current portion

3,154

123

3,277

Total current liabilities

75,998

123

76,121

Operating lease liabilities

26,450

1,670

28,120

Total liabilities

$
368,208

$
1,793

$
370,001

Trulieve Cannabis Corp.

~~The Company recorded operating lease expense, depreciation, and interest expense totaling $~~Notes to Condensed Consolidated Financial Statements

Basis of Measurement~~0.3~~

~~million in the income statement for the three months ended September 30, 2021 that related to these expenses from prior periods. This had an immaterial impact~~

These condensed consolidated financial statements have been prepared on the ~~period recorded~~going concern basis, under the historical cost convention, except for certain financial instruments that are measured at fair value as described herein.

Functional Currency

The functional currency of the Company and its subsidiaries, as determined by management, is the United States (“U.S.”) dollar. These condensed consolidated financial statements are presented in U.S. dollars.

Reclassifications

Certain reclassifications have been made to the condensed consolidated financial statements of prior periods and ~~is correctly reflected for~~ the ~~nine months ended September 30, 2021~~accompanying notes to conform to the current period presentation..

~~NOTE 3. ACQUISITIONS~~Trulieve Cannabis Corp.

~~(a)~~Notes to Condensed Consolidated Financial Statements

The Company analyzed the acquisition under ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, determining Watkins met the definition of a business as Watkins is an existing cultivation facility with inputs, processes, and outputs in place that constitute a business under Topic 805. As a result, the acquisition of Watkins has been accounted for as a business combination. Goodwill represents the premium the Company paid over the fair value of the net tangible assets acquired. The primary reason for the acquisition was to expand the Company's cultivation capacity in Arizona. The goodwill of $24.5 million arising from the acquisition primarily consist of the economies of scale expected from a vertical cannabis market in Arizona.

The following table summarizes the allocation of consideration exchanged for the estimated fair value of tangible assets acquired and liabilities assumed:


(in thousands)
Consideration
Cash	$	27,500
Fair value of consideration exchanged	$	27,500
Recognized amounts of identifiable assets acquired and liabilities assumed:
Inventories	$	2,266
Property and equipment		692
Right of use asset - operating		4,737
Goodwill		24,542
Operating lease liability		(4,737	)
Total net assets acquired	$	27,500

(b) Purplemed Healing Center

On December 28, 2021, the Company acquired 100% of certain assets of Purplemed Healing Center ("Purplemed") including the Medical Marijuana Dispensary License issued by the Arizona Department of Health Services ("ADHS") and the Marijuana Establishment License issued by the ADHS which collectively serve as the Purplemed license providing the ability to operate a marijuana retail sales dispensary as well as the assumption of the associated lease. The Company also acquired the right to operate an additional offsite cultivation business under the Arizona Adult Use Marijuana Act, and the option to purchase full ownership and management of Greenmed, Inc., the Greenmed license, and the Greenmed dispensary. As part of the transaction, the Company assumed the Purplemed loyalty program.

The Company analyzed the acquisition under ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, determining Purplemed did not meet the definition of a business as Purplemed did not have inputs, processes, and outputs in place that constituted a business under Topic 805. As a result, the acquisition of Purplemed has been accounted for as an asset acquisition, whereby all of the assets acquired and liabilities assumed are assigned a carrying amount based on relative fair values. The total consideration was $15.0 million consisting of cash. The acquisition provided for indemnity for pre-closing liabilities. Accordingly, the Company recognized an indemnification asset of $0.5 million offset by associated liabilities based on the information that was available at the date of the acquisition, which is included in the net assets acquired.

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

The net assets were acquired for an aggregate purchase price of $15.0 million.


(in thousands)
Consideration:
Cash	$	15,000
Transaction costs		12
Fair value of consideration exchanged	$	15,012
Recognized amounts of identifiable assets acquired and liabilities assumed:
Prepaid expenses and other current assets	$	531
Right of use asset - operating		271
Intangible asset		15,076
Other current liabilities		(531	)
Deferred revenue		(109	)
Operating lease liability		(226	)
Total net assets acquired	$	15,012

The acquired intangible asset includes a dispensary license which is treated as a definite-lived intangible asset amortized over a 15-year useful life.

On October 1, 2021, (the “Closing Date”), the Company acquired 100% of the common shares of Harvest Health & Recreation, Inc. (“Harvest”) and its portion of variable interest entities in exchange for Subordinate Voting Shares of the Company (the “Transaction”).

Harvest is one of the largest multi-state vertically integrated operators in the cannabis industry in the United States operating from “seed to sale". Harvest operates facilities or provides services to cannabis dispensaries in Arizona, California, Colorado, Florida, Maryland, Nevada, and Pennsylvania, with two provisional licenses in Massachusetts. In addition, Harvest owns CO2 extraction, distillation, purification, and manufacturing technology used to produce a line of cannabis topicals, vapes, and gems featuring cannabinoids and a hemp-derived product line sold in Colorado.

Total consideration was $1.4 billion consisting of Trulieve Subordinate Voting Shares (“Trulieve Shares”) with a fair value of $1.37 billion, stock options, equity classified warrants, restricted stock units and other outstanding equity instruments with a fair value of $18.4 million, and warrant liabilities convertible into equity with a fair value of $3.1 million at the time of the Transaction. The Company incurred $13.0 million in transaction costs related to the acquisition of Harvest as of December 31, 2021. NaN additional transaction costs have been incurred.

The acquisition was accounted for as a business combination in accordance with the Accounting Standards Codification (ASC) 805, Business Combinations. Goodwill represents the premium the Company paid over the fair value of the net tangible and intangible assets acquired. The primary reason for the acquisition was to expand the Company’s retail and cultivation footprint and gain access to new markets. The goodwill of $662.1 million arising from the acquisition primarily consisted of the synergies and economies of scale expected from combining the operations of Trulieve and Harvest including growing the Company's customer base, acquiring assembled workforces, and expanding its presence in new and existing markets. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. Goodwill is subject to the limits of IRC Section 280E under which the Company is only allowed to deduct expenses directly related to the cost of goods sold, therefore goodwill is not deductible.

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

The following table summarizes the allocation of consideration exchanged for the estimated fair value of tangible and identifiable intangible assets acquired and liabilities assumed:


(in thousands)
Consideration:
Trulieve Subordinated Voting Shares	$	1,369,024
Fair value of other equity instruments		18,394
Fair value of warrants classified as liabilities		3,103
Fair value of consideration exchanged	$	1,390,521
Recognized amounts of identifiable assets acquired and liabilities assumed:
Cash and cash equivalents	$	85,318
Restricted cash		3,072
Accounts receivable		3,645
Inventories		92,537
Prepaid expenses and other current assets		100,129
Notes receivable		9,805
Property and equipment		191,801
Right of use assets - operating		73,476
Intangible assets:
Dispensary license		946,000
Trademarks		27,430
Customer relationships		3,500
Other assets		5,289
Accounts payable and accrued liabilities		(58,887	)
Income tax payable		(24,863	)
Deferred revenue		(4,523	)
Operating lease liabilities		(76,558	)
Contingencies		(26,599	)
Notes payable		(285,238	)
Construction finance liabilities		(79,683	)
Other long-term liabilities		(1,085	)
Deferred tax liabilities		(253,986	)
	$	730,580
Non-controlling interest	$	(2,139	)
Goodwill		662,080
Total net assets acquired	$	1,390,521

The acquired intangible assets include dispensary licenses which are treated as definite-lived intangible assets amortized over a 15-year useful life, tradenames amortized over a one to five year useful life, and customer relationships amortized over a one year period.

On acquisition date there was consideration in the form of 1,266,641 stock options (as converted) that had been issued before the acquisition date to employees and non-employees of Harvest. The pre-combination fair value of these awards is $6.2 million. There was consideration in the form of 1,011,095 warrants (1,009,416 equity classified SVS warrants and 1,679 liability classified MVS warrants, as converted) that had been issued before the acquisition date to employees and non-employees of Harvest. The pre-combination fair value of these awards is $7.7 million with $4.6 million representing the equity classified warrants and $3.1 million representing the liability classified warrants. There was consideration in the form of restricted stock units that had been issued before the acquisition date to non-employees of Harvest which vested for services performed pre-combination representing 18,297 SVS. The pre-combination fair value of these awards is $0.5 million. There was additional consideration in the form of other outstanding equity instruments issued before the acquisition date to non-employees which had a pre-combination fair value of $7.1 million.

As part of the acquisition, Harvest entered into a sale agreement to sell their Florida cannabis license for $55.0 million where Trulieve was legally prohibited from holding this license and the sale occurred simultaneously with the Transaction. Therefore, a $55.0 million

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

receivable for the sale proceeds was deemed acquired and recorded. The funds were received subsequent to the closing of the transaction on October 1, 2021.

The Company has not yet finalized their accounting for non-controlling interests on the acquired entities but has recorded preliminary entries in this area. Any subsequent adjustments would be expected to impact non-controlling interest and goodwill. This accounting will be finalized during the measurement period.

Supplemental pro forma information (unaudited)

The unaudited pro forma information for the periods set forth below gives effect to the acquisition of Harvest Health & Recreation Inc. and Keystone Shops, as if the acquisitions had occurred on January 1, 2021. This pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved had the transactions been consummated as of that time nor does it purport to be indicative of future financial operating results.

•

Proforma net revenues for the period ending March 31, 2021 are $287.9 million. Proforma net loss and comprehensive loss attributable to common shareholders for the period ending March 31, 2021 are $2.5 million.

Unaudited pro forma net income reflects the adjustment of sales between the companies, and adjustments for alignment of significant differences in accounting principles and elections.

(d) Keystone Shops

On July 8, 2021, the Company acquired 100% of the membership interests of Anna Holdings, LLC, the sole member of Chamounix Ventures, LLC which holds a permit to operate dispensaries under Keystone Shops (“Keystone Shops”) with locations in Philadelphia, Devon and King of Prussia, Pennsylvania. Total consideration was $55.6 million consisting of $20.3 million in cash, inclusive of net working capital adjustments, and 1,009,336 in Trulieve Subordinate Voting Shares ("Trulieve Shares") with a fair value of $35.4 million. The agreement provides for an additional $5.0 million in consideration which is contingent on the enactment, adoption or approval of laws allowing for adult-use cannabis in ~~the Commonwealth of~~ Pennsylvania. NaN liability ~~has been~~was recorded for this contingent consideration, as it was not estimated to be probable at the time of ~~acquisition.~~acquisition nor as of March 31, 2022. The acquisition was accounted for as a business combination in accordance with the Accounting Standards Codification (ASC) 805, Business Combinations. Goodwill arose because the consideration paid for the business acquisition reflected the benefit of expected revenue growth and future market development. ~~These benefits were not recognized separately from goodwill because they do not meet~~

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

The following table summarizes the ~~recognition criteria~~allocation of consideration exchanged for the estimated fair value of tangible and identifiable intangible assets. Goodwill is subject to the limits of IRC Section 280E under which the Company is only allowed to deduct expenses directly related to the cost of production, therefore goodwill is not deductible.assets acquired and liabilities assumed:


(dollars in thousands)
(in thousands)
Consideration:
Cash	$	20,251		$	20,251
Shares issued upon acquisition		35,385			35,385
Fair value of consideration exchanged	$	55,636		$	55,636
Recognized amounts of identifiable assets acquired and liabilities assumed:
Cash	$	500		$	500
Inventories		1,766			1,766
Prepaid expenses and other current assets		240			240
Property and equipment		1,144			1,144
Right of use asset - finance		1,340			1,340
Intangible assets
Dispensary license		27,000			27,000
Tradename		100			100
Favorable leasehold interests, net		86			86
Goodwill		40,072			39,703
Other assets		40			40
Accounts payable and accrued liabilities		(878	)		(878	)
Income tax payable		(2,892	)		(2,892	)
Operating lease liabilities		(1,340	)		(1,340	)
Other long-term liabilities		(2,179	)		(2,179	)
Deferred tax liability		(9,363	)		(8,994	)
Total net assets acquired	$	55,636		$	55,636

The acquired intangible assets include a dispensary license which is treated as a definite-lived intangible asset amortized over a 15-year useful life, as well as tradename and net favorable leasehold interests which were fully amortized in the period of acquisition due to useful life and materiality considerations.

9(e) Nature’s Remedy of Massachusetts, Inc.

On June 30, 2021, the Company completed an asset purchase agreement whereby Trulieve acquired a licensed, but not yet operating, adult-use dispensary location from Nature’s Remedy of Massachusetts, Inc. (“Nature’s Remedy”). The Company analyzed the acquisition under ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, determining Nature’s Remedy did not meet the definition of a business as Nature’s Remedy did not have inputs, processes, and outputs in place that constituted a business under Topic 805. As a result, the acquisition of Nature’s Remedy has been accounted for as an asset acquisition, whereby all of the assets acquired and liabilities assumed are assigned a carrying amount based on relative fair values. Total consideration was $16.2 million consisting of $7.0 million in cash and 237,881 in Trulieve Shares, with a fair value of $9.1 million, and less than $0.1 million in transaction costs.

~~(b)~~Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

The following table summarizes the allocation of consideration exchanged for the estimated fair value of tangible and identifiable intangible assets acquired and liabilities assumed:


(in thousands)
Consideration:
Cash	$	7,000
Shares issued upon acquisition		9,139
Transaction costs		23
Fair value of consideration exchanged	$	16,162
Recognized amounts of identifiable assets acquired and liabilities assumed:
Prepaid expenses and other current assets	$	12
Property and equipment		1,006
Right of use asset - finance		799
Intangible assets		15,274
Accounts payable and accrued liabilities		(335	)
Finance lease liability		(594	)
Total net assets acquired	$	16,162

The acquired intangible asset is represented by the adult-use license and is treated as a definite-lived intangible asset amortized over a 15-year useful life.

(f) Patient Centric of Martha's Vineyard

On July 2, 2021, the Company acquired certain assets of Patient Centric of Martha’s Vineyard (“PCMV”) including the rights to a Provisional Marijuana Retailers License from the Massachusetts Cannabis Control Commission, the right to exercise an option held by PCMV to lease real property in Framingham, Massachusetts for use as a marijuana retailer, and necessary municipal entitlements to operate as a marijuana retailer at the property. Total consideration was 258,383 in Trulieve Shares, of which 10,879 are subject to a holdback for six months as security for any indemnity claims by the Company under the asset purchase agreement. The fair value of the equity ~~exchange~~exchanged was $10.0 million. The Company analyzed the acquisition under ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, determining PCMV did not meet the definition of a business as PCMV did not have inputs, processes, and outputs in place that constituted a business under Topic 805. As a result, the acquisition of PCMV has been accounted for as an asset acquisition, whereby all of the assets acquired and liabilities assumed are assigned a carrying amount based on relative fair values.

~~(dollars in thousands)~~


(in thousands)
Consideration:
Shares issued upon acquisition	$	10,012
Transaction costs		18
Fair value of consideration exchanged	$	10,030
Recognized amounts of identifiable assets acquired and liabilities assumed:
Right of use asset - finance	$	1,756
Intangible asset		10,594
Finance lease liabilities		(2,320	)
Total net assets acquired	$	10,030

~~Consideration:~~

~~Shares issued upon acquisition~~

~~10,012~~

~~Transaction costs~~

~~Fair value of consideration exchanged~~

~~10,030~~

~~Recognized amounts of identifiable assets acquired and liabilities assumed:~~

~~Right of use asset - finance~~

~~1,756~~

~~Intangible assets~~

~~Dispensary license~~

~~13,298~~

~~Finance lease liabilities~~

(~~2,321~~

)

~~Deferred tax liability~~

(~~2,703~~

)

~~Total net assets acquired~~

~~10,030~~

The acquired intangible asset is represented by the adult-use license and is treated as a definite-lived intangible asset amortized over a 15-year useful life.

~~(c) Nature’s Remedy of Massachusetts, Inc.~~

On June 30, 2021, the Company completed an asset purchase agreement whereby Trulieve acquired a licensed, but not yet operating, adult-use dispensary location from Nature’s Remedy of Massachusetts, Inc. (“Nature’s Remedy”). The Company analyzed the acquisition under ASU 2017-01, ~~Business Combinations (Topic 805): Clarifying the Definition of a Business,~~ determining Nature’s Remedy did not meet the definition of a business as Nature’s Remedy did not have inputs, processes, and outputs in place that constituted a business under Topic 805. As a result, the acquisition of Nature’s Remedy has been accounted for as an asset acquisition, whereby all of the assets acquired and liabilities assumed are assigned a carrying amount based on relative fair values. During the third quarter of 2021, the Company recorded an adjustment of $~~2.6~~ million increasing the cost of the acquisition due to an adjustment to the fair value of the equity consideration and updated the purchase price allocation accordingly, which updated equity consideration from contract value to fair value as of the closing date, and also updated the associated deferred tax liability. ~~This adjustment resulted in an updated total consideration of $16.2~~ ~~million consisting of $7.0~~ ~~million in cash and~~ ~~237,881~~ ~~in Trulieve Shares with an updated fair value of $9.1~~

~~million and less than $0.1~~ ~~million in transaction costs. Refer to "Note 2. Basis of Presentation" under "Revisions of Previously Issued Financial Statements" above for additional details. The adjusted net assets acquired are as follows:~~

(dollars in thousands)

Consideration:

Cash

$
7,000

Shares issued upon acquisition

9,139

Transaction costs

23

Fair value of consideration exchanged

$
16,162

Recognized amounts of identifiable assets acquired and liabilities assumed:

Prepaid expenses and other current assets

$
12

Property and equipment

1,006

Right of use asset - finance

799

Intangible assets

Dispensary license

19,630

Accounts payable and accrued liabilities

(335
)
Finance lease liability

(594
)
Deferred tax liability

(4,356
)
Total net assets acquired

$
16,162

~~The acquired intangible asset is represented by the adult-use license and is treated as a definite-lived intangible asset amortized over a~~ 15~~-year useful life.~~

~~(d)~~(g) Solevo Wellness West Virginia, LLC

On June 8, 2021, the Company acquired 100% of the membership interests of Solevo Wellness West Virginia, LLC (“Solevo WV”) which holds three West Virginia dispensary licenses. The Company analyzed the acquisition under ASU 2017-01, Business

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

Combinations (Topic 805): Clarifying the Definition of a Business, determining Solevo WV did not meet the definition of a business as substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset. Therefore, the transaction has been accounted for as an asset acquisition. ~~During the third quarter of 2021, the Company recorded an adjustment of $0.1~~ ~~million decreasing the cost of the acquisition due to an adjustment to the fair value of the equity~~Total consideration which updated equity consideration originally recorded at contract value to fair value as of the closing date, and also updated the associated deferred tax liability. This adjustment resulted in an updated total consideration ofwas $0.8 million consisting of $0.2 million in cash, 11,658 in Trulieve Shares with ~~an updated~~a fair value of $0.4 million, $0.1 million in debt forgiveness and less than $0.1 million in transaction costs. The consideration of $0.8 million was allocated to acquired assets of $~~1.0~~0.8 million, which are treated as definite-lived intangible assets amortized over a 1515-year~~-year~~ useful ~~life, offset by a related deferred tax liability of $~~life.~~0.2~~ ~~million. Refer to "Note 2. Basis of Presentation" under "Revisions of Previously Issued Financial Statements" above for additional details.~~

~~(e)~~

(h) Mountaineer Holding, LLC

On May 6, 2021, the Company acquired 100% of the membership interests of Mountaineer Holding LLC (“Mountaineer”) which holds a cultivation permit and two dispensary permits in West Virginia. The Company analyzed the acquisition under ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, determining Mountaineer did not meet the definition of a business as substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset. Therefore, the transaction has been accounted for as an asset acquisition. ~~During the third quarter of 2021, the Company recorded an adjustment of $0.5~~ ~~million decreasing the cost of the acquisition due to an adjustment to the fair value of the equity~~Total consideration which updated equity consideration originally recorded at contract value to fair value as of the closing date, and also updated the associated deferred tax liability. This adjustment resulted in an updated total consideration ofwas $5.5 million, consisting of $3.0 million in cash and 60,342 in Trulieve Shares with a fair value of $2.5 million. The consideration of $5.5 million has been allocated to the $~~7.0~~5.5 million of acquired assets which are treated as definite-lived intangible assets and amortized over a 1515-year~~-year~~ useful ~~life, offset by a related deferred tax liability of $1.5~~ ~~million. Refer to "Note 2. Basis of Presentation" under "Revisions of Previously Issued Financial Statements" above for additional details.~~

~~(f) PurePenn, LLC and Pioneer Leasing & Consulting, LLC~~

~~On November 12, 2020, the Company acquired~~ ~~100~~% of the membership interests of both PurePenn, LLC, which holds a permit to cultivate and process medical marijuana in Pennsylvania, and Pioneer Leasing & Consulting, LLC (collectively “PurePenn”). The purpose of this acquisition was to operate the cultivation and manufacturing facility located in McKeesport, Pennsylvania. Trulieve acquired PurePenn for an upfront payment valued at $~~48.7~~ ~~million, comprised of~~ ~~1,298,964~~ ~~in Trulieve Shares with a fair value of $29.7~~ ~~million and $19.0~~ ~~million in cash, plus a potential earn-out payment of up to~~ ~~2,405,488~~ Trulieve Shares based on the achievement of certain agreed upon EBITDA milestones. The earn-out period is through the end of 2021. The acquisition was accounted for as a business combination in accordance with the Accounting Standards Codification (ASC) 805, Business Combinations. As of September 30, 2021, total transaction costs related to the acquisition were approximately $~~1.8~~ million. Goodwill arose because the consideration paid for the business acquisition reflected the benefit of expected revenue growth and future market development. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. Goodwill is subject to the limits of IRC Section 280E under which the Company is only allowed to deduct expenses directly related to the cost of production, therefore goodwill is not deductible.

For the three months ended June 30, 2021, the Company recorded an adjustment to the initial valuation of shares issued upon acquisition, which increased the fair value of the consideration exchanged and the estimated purchase price by $~~2.7~~ ~~million and increased goodwill by $2.7~~ million and we recorded an adjustment to the initial valuation of contingent consideration payable in shares, which reduced contingent consideration payable in shares and the estimated purchase price by $~~3.0~~ ~~million and decreased goodwill by $3.0~~ ~~million. For the three months ended September 30, 2021, the Company recorded an adjustment to the deferred tax liability decreasing goodwill and the associated deferred tax liability by $0.6~~ ~~million.~~

~~The following table summarizes the allocation of consideration exchanged for the estimated fair value of tangible and identifiable intangible assets acquired and liabilities assumed:~~

(dollars in thousands)

Consideration:

Cash

$
19,000

Shares issued upon acquisition

29,711

Contingent consideration payable in shares

46,951

Fair value of consideration exchanged

$
95,662

Recognized amounts of identifiable assets acquired and liabilities assumed:

Cash

$
563

Accounts receivable

1,300

Prepaid expenses and other current assets

376

Inventories

7,461

Property and equipment, net

26,233

Intangible assets, net:

State license

45,310

Moxie license

2,960

Tradename

580

Goodwill

46,349

Other assets

478

Accounts payable and accrued liabilities

(2,189
)
Construction finance liability

(17,413
)
Deferred tax liability

(16,346
)
Total net assets acquired

$
95,662

~~(g) Keystone Relief Centers, LLC~~

~~On November 12, 2020, the Company acquired~~ ~~100% of the membership interests of Keystone Relief Centers, LLC (referred to herein as “Solevo Wellness”), which holds a permit to operate~~ 3 ~~medical marijuana dispensaries in the Pittsburgh, Pennsylvania area. Trulieve acquired Solevo for an upfront purchase price of $21.0~~ ~~million, comprised of $10.0~~ ~~million in cash and~~ ~~481,097~~ ~~in Trulieve Shares with a fair value of $11.0~~ ~~million, plus a potential earn-out payment of up to~~ ~~721,647~~ Trulieve Shares based on the achievement of certain agreed upon EBITDA milestones. The earn-out period is through the end of 2021. The acquisition was accounted for as a business combination in accordance with the Accounting Standards Codification (ASC) 805, Business Combinations.~~As of September 30, 2021, total transaction costs related to the acquisition were approximately $0.9~~ ~~million. Goodwill arose because the~~life.

consideration paid for the business acquisition reflected the benefit of expected revenue growth and future market development. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. Goodwill is subject to the limits of IRC Section 280E under which the Company is only allowed to deduct expenses directly related to the cost of production, therefore goodwill is not deductible.

~~During 2021, the purchase price allocations were adjusted, primarily to net working capital, goodwill and intangible assets. For the three months ended March 31, 2021, we recorded an adjustment of $3.8~~ ~~million to the initial valuation amount of intangible assets for the dispensary license, increasing the dispensary license balance by $3.8~~ ~~million and decreasing goodwill by $3.8~~ ~~million. For the three months ended June 30, 2021, we recorded an adjustment to the initial valuation of shares issued upon issuance, which increased the fair value of the consideration exchanged by $1.0~~ ~~million and increased goodwill by $1.0~~ million, and we recorded an adjustment to the initial valuation of contingent consideration payable in shares, which increased contingent consideration payable in shares and the estimated purchase price by $~~0.2~~ ~~million and increased goodwill by $0.2~~ ~~million. For the three months ended September 30, 2021, the Company recorded an adjustment to the deferred tax liability increasing goodwill and the associated deferred tax liability by $1.2~~ ~~million.~~

~~The following table summarizes the final allocation of consideration exchanged for the estimated fair value of tangible and identifiable intangible assets acquired and liabilities assumed:~~

(dollars in thousands)

Consideration:

Cash

$
10,000

Shares issued upon acquisition

11,004

Contingent consideration payable in shares

15,249

Net working capital adjustment

624

Fair value of consideration exchanged

$
36,877

Recognized amounts of identifiable assets acquired and liabilities assumed:

Cash

$
1,229

Accounts receivable

117

Prepaid expenses and other current assets

91

Inventories

2,337

Property and equipment, net

2,245

Right of use asset

2,156

Intangible assets, net:

Dispensary license

19,890

Tradename

930

Goodwill

17,985

Accounts payable and accrued liabilities

(790
)
Lease liability

(2,156
)
Deferred tax liability

(7,157
)
Total net assets acquired

$
36,877

~~NOTE~~ ~~4. INVENTORY~~

~~The Company’s inventory includes the following at September 30, 2021 and December 31, 2020:~~

September 30, 2021

December 31, 2020

(dollars in thousands)

Raw material

Cannabis plants

$
19,419

$
10,661

Harvested cannabis and packaging

23,529

11,233

Total raw material

42,948

21,894

Work in process

63,952

54,780

Finished goods-unmedicated

3,473

3,908

Finished goods-medicated

23,501

17,730

Total inventories

$
133,874

$
98,312

NOTE 5. ~~PROPERTY & EQUIPMENT~~ACCOUNTS RECEIVABLE

~~At September 30, 2021~~As of March 31, 2022 and December 31, ~~2020, Property and Equipment~~2021, Accounts receivable, net consisted of the following:

September 30, 2021

December 31, 2020

(dollars in thousands)

Land

$
7,468

$
5,878

Buildings and improvements

288,133

156,372

Construction in progress

162,528

129,588

Furniture and equipment

93,485

51,714

Vehicles

349

351

Total

551,963

343,903

Less: accumulated depreciation

(50,854
)

(29,858
)
Total property and equipment, net

$
501,109

$
314,045


	March 31, 2022			December 31, 2021
	(in thousands)
Trade receivables	$	13,633		$	9,363
Less: allowance for credit losses		(851	)		(509	)
Accounts receivable, net	$	12,782		$	8,854

NOTE 6. NOTES RECEIVABLE

As of March 31, 2022 and December 31, 2021, Notes receivable, net consisted of the following:


	March 31, 2022			December 31, 2021
	(in thousands)
Promissory note acquired from Harvest maturing in November 2025. Secured by certain assets.	$	8,659		$	8,827
Convertible note receivable dated November 2021 maturing in November 2024.		4,276			4,124
Promissory notes acquired from Harvest maturing in February 2022. Secured by certain assets.		—			850
Notes receivable		12,935			13,801
Less: discount on notes receivable		(113	)		(124	)
Total notes receivable, net of discounts		12,822			13,677
Less: current portion of notes receivable		(634	)		(1,530	)
Notes receivable	$	12,188		$	12,147

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

In October 2021, the Company acquired a note receivable with the Harvest acquisition. The note receivable is originally dated November 2020 maturing in November 2025. The note had an original principal balance of $12.0 million and accrues interest at a rate of 7.5% per annum with monthly interest and principal payments of $0.1 million.

In October 2021, the Company acquired notes receivable with the Harvest acquisition. The notes receivable are originally dated February 2021 maturing in February 2022. The notes had an original principal balance of $0.9 million and accrue interest at a rate of 10% per annum with interest only payments due monthly. These notes were repaid in full in February 2022.

As part of the acquisition of Harvest, we acquired $9.8 million in notes receivable on October 1, 2021. There were 0 notes receivable outstanding prior to October 1, 2021.

See Note 4. Acquisitions for further details of the Harvest acquisition.

In November 2021, the Company entered into a convertible note receivable agreement for a principal amount of $4.1 million that matures in November 2024. The note accrues interest monthly at 9.75%, and accrued interest is added to the principal balance at each quarter end. The note is convertible to equity of the holder at our option at any time prior to maturity. Further, the note was issued at a discount of 3% or $0.1 million, which is accreted to the note receivable balance over the term of the note.

During the three months ended March 31, 2022, the Company recorded interest income of $0.4 million in other income (expense), net on the condensed consolidated statements of operations and comprehensive (loss) income. The Company had 0 accrued interest receivable as of March 31, 2022, and $0.1 million as of December 31, 2021, included in prepaid expenses and other current assets on the condensed consolidated balance sheets.

Stated maturities of notes receivable are as follows as of March 31, 2022:


	Expected principal payments
	(in thousands)
Remaining 2022	$	454
2023		728
2024		5,060
2025		6,693
2026		—
Thereafter		—
Total		12,935
Less: discount on notes receivable		(113	)
Total	$	12,822

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

NOTE 7. INVENTORY

As of March 31, 2022 and December 31, 2021, Inventories, net consisted of the following:


	March 31, 2022		December 31, 2021
	(in thousands)
Raw material
Cannabis plants	$	34,271	$	31,279
Packaging and supplies		41,453		40,326
Total raw material		75,724		71,605
Work in process		99,671		94,249
Finished goods-unmedicated		9,213		4,824
Finished goods-medicated		51,819		41,510
Total inventories	$	236,427	$	212,188

NOTE 8. PROPERTY & EQUIPMENT

As of March 31, 2022 and December 31, 2021, Property and equipment, net consisted of the following:


	March 31, 2022			December 31, 2021
	(in thousands)
Land	$	30,884		$	32,904
Buildings and improvements		601,195			435,185
Construction in progress		86,431			234,198
Furniture and equipment		163,518			140,281
Vehicles		985			959
Total		883,013			843,527
Less: accumulated depreciation		(77,014	)		(63,611	)
Total property and equipment, net	$	805,999		$	779,916

Capitalized interest for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and March 31, 2021 totaled $~~2.2~~1.5 million and $~~4.4~~ ~~million, respectively. Capitalized interest for the three and nine months ended September 30, 2020 totaled $1.3~~ ~~million and $2.1~~ ~~million, respectively.~~

~~Depreciation expense for the three and nine months ended September 30, 2021 totaled $8.1~~ ~~million and $21.0~~0.4 million, respectively. Depreciation expense for the three ~~and nine~~ months ended ~~September 30, 2020~~March 31, 2022 and March 31, 2021 totaled $~~3.9~~15.5 million and $~~10.7~~5.6 million, respectively.

During the three months ended March 31, 2022, the Company recorded a loss on the disposal of property and equipment of $3.0 million and an impairment of $0.3 million which is the result of repositioning of assets in the southeast. This loss was recorded in impairment and disposal of long-lived assets in the condensed consolidated statements of operations and comprehensive (loss) income. There was 0 loss on disposal of property and equipment during the three months ended March 31, 2021.

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

NOTE 9. INTANGIBLE ASSETS & GOODWILL

~~Certain prior period amounts have been reclassified to conform to the current period presentation. Internal use software with a net book value of $~~Intangible assets~~3.7~~

million was reclassified from “Property and equipment, net” to “Intangible assets, net” in the consolidated balance sheet as of December 31, 2020. Property and equipment with a net book value of $~~50.0~~ ~~million was reclassified from construction in progress to land, buildings and improvements, and furniture and equipment of December 31.~~

~~NOTE~~ ~~6. INTANGIBLE ASSETS & GOODWILL~~

~~At September 30, 2021~~As of March 31, 2022 and December 31, ~~2020, definite-lived intangible~~2021, Intangible assets, net consisted of the following:

September 30, 2021

(dollars in thousands)

Net
amount

Adjustments to
purchase price allocation

Additions

Amortization
expense

Net
amount

Licenses

$
84,517

$
3,061

$
68,493

$
(5,593
)

$
150,478

Internal use software

3,656

—

3,589

(529
)

6,716

Moxie brand

2,828

—

—

(740
)

2,088

Tradenames

2,109

—

100

(741
)

1,468

Customer relationship

683

—

—

(151
)

532

Miscellaneous

7

—

86

(93
)

—

$
93,800

$
3,061

$
72,268

$
(7,847
)

$
161,282


	March 31, 2022
	Gross Carrying Amount		Accumulated Amortization		Net Book Value
	(in thousands)
Licenses	$	1,106,658	$	42,819	$	1,063,839
Trademarks		27,430		5,617		21,813
Internal use software		9,588		1,496		8,092
Tradenames		4,862		2,512		2,350
Customer relationships		4,536		2,352		2,184
Total	$	1,153,074	$	54,796	$	1,098,278

December 31, 2020

(dollars in thousands)

Net amount

Acquired
license agreements

Additions

Amortization expense

Net amount

Licenses

$
24,538

$
887

$
61,400

$
(2,308
)

$
84,517

Internal use software

3,656

—

—

—

3,656

Moxie brand

—

—

2,960

(132
)

2,828

Tradenames

800

—

1,510

(201
)

2,109

Customer relationship

883

—

—

(200
)

683

Miscellaneous

25

—

—

(18
)

7

Trademarks

134

—

—

(134
)

—

$
30,036

$
887

$
65,870

$
(2,993
)

$
93,800


	December 31, 2021
	Gross Carrying Amount		Accumulated Amortization		Net Book Value
	(in thousands)
Licenses	$	1,106,658	$	25,352	$	1,081,306
Trademarks		27,430		2,809		24,621
Internal use software		7,374		1,119		6,255
Tradenames		4,862		2,168		2,694
Customer relationships		4,536		1,430		3,106
Total	$	1,150,860	$	32,878	$	1,117,982

Amortization expense for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and 2021 was $~~3.3~~21.9 million and $~~7.8~~ ~~million, respectively. Amortization expense for the three and nine months ended September 30, 2020 was $0.5~~ ~~million and $1.7~~2.0 million, respectively.

The following table outlines the estimated future annual amortization expense related to ~~all~~ intangible assets as of ~~September 30, 2021:~~March 31, 2022:

Estimated amortization

(dollars in thousands)

Remaining 2021

$
3,326

2022

13,887

2023

13,320

2024

12,349

2025

11,895

Thereafter

106,505

$
161,282


	Estimated amortization
	(in thousands)
Remaining 2022	$	64,964
2023		82,161
2024		80,419
2025		78,392
2026		76,894
Thereafter		715,448
	$	1,098,278

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

Goodwill

The changes in the carrying amount of Goodwill arose from ~~the acquisition of PurePenn, LLC, Pioneer Leasing & Consulting, Solevo Wellness, and Keystone Shops, see~~ ~~“Note 3 - Acquisitions”. The Company last tested for impairment in the fourth quarter of the year ended December 31, 2020.~~

~~At September 30, 2021, Goodwill consisted of~~ the following:

(dollars in thousands)

At January 1, 2020

7,316

Acquisition of PurePenn, LLC and Pioneer Leasing & Consulting, LLC

47,311

Acquisition of Solevo Wellness

19,473

At December 31, 2020

74,100

Measurement period purchase price allocation adjustments of Solevo Wellness

(2,639
)
Measurement period purchase price allocation adjustments of PurePenn, LLC and
Pioneer Leasing & Consulting, LLC

(338
)
At June 30, 2021

71,123

Acquisition of Keystone Shops

40,072

Measurement period purchase price allocation adjustments of Solevo Wellness

1,150

Measurement period purchase price allocation adjustments of PurePenn, LLC and
Pioneer Leasing & Consulting, LLC

(624
)
At September 30, 2021

$
111,721


	Three Months Ending March 31, 2022
	(in thousands)
As of December 31, 2021	$	765,358
Acquisition of Watkins		24,542
As of March 31, 2022	$	789,900

NOTE 7.10. NOTES PAYABLE

AtAs of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020, notes~~2021, Notes payable consisted of the following:

September 30, 2021

December 31, 2020

(dollars in thousands)

Promissory note dated April 10, 2017, with annual interest at 12%, due between April and July 2022

$
4,000

$
4,000

Promissory note dated December 7, 2017, with annual interest at 12%, secured by certain property located in Miami, FL due December 2021

2,000

2,000

Total notes payable

6,000

6,000

Less current portion

(6,000
)

(2,000
)
Long-term notes payable

$
—

$
4,000


	March 31, 2022			December 31, 2021
	(in thousands)
Promissory notes dated October 1, 2021, maturing in October 2022. Monthly interest payments due of 4.75%. Secured by mortgaged property with a $6 million book value.		6,156			6,156
Promissory note acquired in Harvest acquisition dated February 2020, maturing in February 2023. Monthly interest payments due at 5.5%.		2,670			4,699
Promissory note dated July 2018, maturing in July 2023. Monthly interest payments due of 4% per annum. Secured by certain assets.		1,103			1,113
Promissory note of consolidated variable-interest entity dated February 2022, maturing February 2029. Monthly interest payments due of 8%.		930			—
Promissory note dated October 2019, maturing in October 2024. Monthly interest payments due of 5.5%. Principal balance due at maturity.		800			829
Promissory note acquired in Harvest acquisition dated August 2018, maturing in August 2024. Monthly interest payments due of 2%. Secured by certain assets.		928			1,022
Promissory note acquired in Harvest acquisition dated January 2020, maturing in May 2023. Quarterly interest payments due of 2%.		325			425
Promissory note acquired in Harvest acquisition dated April 2021, maturing in April 2026. Principal due at maturity. Secured by equipment.		56			60
Promissory note acquired in Harvest acquisition dated January 2020, maturing in January 2023. Monthly interest payments due of 2%.		45			65
Promissory notes of consolidated variable-interest entities acquired in Harvest Acquisition. Maturing December 2022 and 2029, interest ranging from 5.25% to 8.25%. Secured by real-estate. In the first quarter of 2022 these notes were fully paid.		—			2,231
Total notes payable		13,013			16,600
Less: Debt discount		(56	)		(92	)
Less: Current portion of notes payable		(9,481	)		(10,052	)
Notes payable	$	3,476		$	6,456

1519

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

~~Stated~~As of March 31, 2022, stated maturities of notes payable are as follows:

As of September 30,

(dollars in thousands)

2021

$
2,000

2022

4,000

$
6,000


	(in thousands)
Remaining 2022	$	6,697
2023		4,711
2024		657
2025		14
2026		4
Thereafter		930
Total	$	13,013

~~All notes payable were fully paid off during the fourth quarter of 2021.~~

~~NOTE~~ ~~8. NOTES PAYABLE RELATED PARTY~~

~~At September 30, 2021 and December 31, 2020, notes payable related party consisted of the following:~~

September 30, 2021

December 31, 2020

(dollars in thousands)

Notes payable due to related parties, with varying interest
rates between 8% to 12% annual, with varying maturity dates

$
12,000

$
12,011

Less current portion

(12,000
)

(12,011
)
Non-current portion

$
—

$
—

~~Stated maturities of notes payable to related parties are as follows:~~

(dollars in thousands)

2022

$
12,000

$
12,000

~~In March 2021, the~~ 2 ~~unsecured promissory notes (the “Traunch Four Note” and the “Rivers Note”) were amended to extend the maturity~~ ~~one year~~ to ~~May 2022, all other terms remain unchanged. In the fourth quarter of 2021, the unsecured promissory notes were fully paid.~~

NOTE 119.. PRIVATE PLACEMENT NOTES

2024 Notes

In 2019, the Company completed two private placement arrangements (the “June Notes” and the “November Notes”), each comprised of 5-year senior secured promissory notes with a face value of $70.0 million and $60.0 million, respectively. Both notes accrue interest at an annual rate of 9.75%, payable semi-annually, in equal installments, in arrears on June 18 and December 18 of each year. The purchasers of the June Notes received warrants to purchase 1,470,000 Subordinate Voting Shares and the purchasers of the November Notes received warrants to purchase 1,560,000 Subordinate Voting Shares, which can be exercised for three years after closing.

~~The fair value of~~During the three months ended March 31, 2022 and 2021, accretion expense for the June Notes was ~~determined to be~~ $~~63.9~~0.4 million ~~using~~and $0.4 million, respectively. During the three months ended March 31, 2022 and 2021, accretion expense for the November Notes was $0.4 million and $0.3 million, respectively.

2026 Notes

On January 28, 2022, the Company closed on a second tranche private placement of 8% Senior Secured Notes (the "2026 Notes") for aggregate gross proceeds of $75.6 million. The 2026 Notes bear interest at a rate of 8% per annum, payable semi-annually in equal installments until the maturity date, unless earlier redeemed or repurchased. The 2026 Notes will mature on October 6, 2026, and may be redeemed in whole or in part, at the Company's option, at any time, on or after October 6, 2023, at the applicable redemption price.TheCompanyintendstousethenetproceedsforcapitalexpendituresandothergeneralcorporatepurposes. Duringthe three months ended March 31, 2022,accretionexpensefortheJanuary2026Noteswaslessthan$0.1million.

On October 6, 2021, the Company closed its private placement of 8% Senior Secured Notes (the "2026 Notes") for aggregate gross proceeds of $350.0 million and net proceeds of $342.6 million. The 2026 Notes were issued at 100% face value, bear an interest rate of ~~13.32~~8% ~~which~~per annum payable semi-annually in equal installments until the maturity date, unless earlier redeemed or repurchased. The 2026 Notes mature on October 6, 2026, and may be redeemed in whole or in part, at the Company's option, at any time, on or after October 6, 2023, at the application redemption price set forth in the Indenture. The Company used a portion of the net proceeds to redeem certain outstanding indebtedness of Harvest and intends to use the remaining net proceeds for capital expenditures and other general corporate purposes. During the three months ended March 31, 2022 the Company ~~estimates would have been the coupon rate required to issue the June Notes had the financing not included the June Warrants. The fair value of the June Warrants was determined to be~~incurred $~~4.7~~0.3 million ~~using the Black-Scholes option pricing model and the following assumptions: share price: C$~~in accretion expense.~~14.48; exercise price: C$17.25; expected life:~~ 3 ~~years; annualized volatility:~~ ~~49.96%; dividend yield:~~ 0~~%; discount rate:~~ ~~1.92%; C$ exchange rate:~~ ~~1.34~~.

~~The fair value of the November Notes was determined to be $54.5~~ ~~million using an interest rate of~~ ~~13.43~~% which the Company estimates would have been the coupon rate required to issue the notes had the financing not included the November Warrants. The fair value of the November Warrants was determined to be $~~4.4~~ ~~million using the Black-Scholes option pricing model and the following assumptions: share price: C$14.29; exercise price: C$17.25; expected life:~~ ~~2.6~~ ~~years; annualized volatility:~~ ~~48.57%; dividend yield:~~ 0~~%; discount rate:~~ ~~1.92%; C$ exchange rate:~~ ~~1.32~~.

~~For~~Accretion expense on the ~~three and nine months ended September 30, 2021 accretion expense was~~ $~~0.8~~ ~~million and $2.3~~ ~~million respectively. For the three and nine months ended September 30, 2020, accretion expense was $0.7~~ ~~million and $2.1~~ ~~million, respectively. Accretion expense~~private placement notes is included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive (loss) income.

1620

~~Because~~Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

Scheduled maturities of the ~~Canadian denominated exercise price,~~principal portion of private placement notes, net outstanding as of March 31, 2022, are as follows:


	(in thousands)
Remaining 2022		1,874
2023		0
2024		130,000
2025		0
2026		425,000
Thereafter		—
Total private placement notes		556,874
Less: Unamortized debt discount & issuance costs		(17,297	)
Less: current portion		(1,874	)
Private placement notes, net	$	537,703

NOTE 12. LEASES

The Company leases real estate used for dispensaries, production plants, and corporate offices. Lease terms for real estate generally range from five to ten years. Most leases include options to renew for varying terms at the ~~June~~Company’s sole discretion. Other leased assets include passenger vehicles, trucks, and ~~November Warrants did~~equipment. Lease terms for these assets generally range from three to five years. Lease right-of-use assets and liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date.

Leases with an initial term of 12 months or less are not ~~qualify to be classified within equity~~recorded on the balance sheet. Lease agreements for some locations provide for rent escalations and ~~were therefore classified~~renewal options. Certain real estate leases require payment for taxes, insurance and maintenance which are considered non-lease components. The Company accounts for real estate leases and the related fixed non-lease components together as ~~derivative liabilities at fair value with changes~~a single component.

During the three months ending March 31, 2022, the Company recorded a loss on disposal of Operating right of use assets of $10.5 million which is the result of repositioning of assets in ~~fair value charged or credited to earnings~~the southeast. This loss was recorded in impairment and disposal of long-lived assets in the condensed consolidated statements of operations and comprehensive ~~income prior to December 10, 2020.~~(loss) income.

On December 10, 2020, the Company entered into a Supplemental Warrant Indenture with Odyssey Trust Company pursuant to which it amended the terms of the issued and outstanding subordinate voting share purchase warrants of the Company (the “Public Warrants”) to convert the exercise price of the Public Warrants to $~~13.47~~ ~~per share, the U.S. dollar equivalent of the Canadian dollar exercise price of the Public Warrants of C$17.25. The U.S. dollar exercise price was determined using the U.S. dollar exchange rate published by the Bank of Canada as at the close of business on December 9, 2020 of C$1.00 = $0.781. The June Warrants and November Warrants converted to equity as per ASC 815-40, at an expense of $25.5~~ ~~million and $27.1~~ ~~million, respectively.~~

~~The $130.0~~ ~~million principal amount of the June and November Notes are due in June~~ ~~2024~~.

~~Scheduled annual maturities of the principal portion of long-term debt outstanding at September 30, 2021 in the successive five-year period and thereafter are summarized below:~~

Private placement notes

(dollars in thousands)

2021

$
—

2022

—

2023

—

2024

130,000

2025

—

Thereafter

—

Total debt

130,000

Less: unamortized debt issuance costs

(10,522
)
Net debt

$
119,478

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

~~NOTE~~ ~~10. LEASES~~

The following table provides the components of lease cost recognized in the condensed consolidated ~~statement~~statements of operations and comprehensive (loss) income for the three ~~and nine~~ months ended ~~September 30, 2021~~March 31, 2022 and ~~2020:~~2021:


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,					For the Three Months Ended March 31,
Lease Cost	2021		2020		2021		2020
									Statement of operations and comprehensive (loss) income location	2022		2021
	(dollars in thousands)									(in thousands)
Operating lease cost		2,483		1,545		5,751		4,087	Cost of goods sold, sales and marketing, general and administrative	$	6,093	$	1,573
Finance lease cost:
Amortization of lease assets		1,990		1,496		5,357		3,688	Cost of goods sold, sales and marketing, general and administrative		2,515		1,570
Interest on lease liabilities		1,177		782		2,914		1,801	Interest expense		1,579		779
Finance lease cost		3,167		2,278		8,271		5,489			4,094		2,349
Variable lease cost		2,529		28		3,139		310	Cost of goods sold, sales and marketing, general and administrative		1,934		395
Short term lease expense									Cost of goods sold, sales and marketing, general and administrative		99		—
Total lease cost	$	8,179	$	3,851	$	17,161	$	9,886		$	12,220	$	4,317

~~Weighted average discount rate and remaining~~Short term lease ~~term~~expense for the ~~nine~~three months ended ~~September 30,~~March 31, 2022 and 2021, ~~are~~was nominal. During the three months ended March 31, 2022 and 2021, we earned a nominal amount of sublease income which is recorded in other income on the consolidated statements of operations and comprehensive (loss) income.

Other information related to operating and finance leases is as follows:

Operating
lease

Finance
lease

Weighted average discount rate

8.75
%

8.46
%
Weighted average remaining lease term (in years)

8.67

8.20


	Three Months Ended March 31,
	2022		2021
	(in thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		5,387		1,424
Operating cash flows from finance leases		1,579		802
Financing cash flows from finance leases		1,421		1,028
Lease assets obtained in exchange for new lease liabilities:
Operating leases		9,566		5,613
Finance leases		6,301		5,084

1722

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements


	March 31, 2022			December 31, 2021
	(in thousands)
Weighted average discount rate:
Operating leases		9.58	%		9.69	%
Finance leases		8.65	%		8.68	%
Weighted average remaining lease term (in years):
Operating leases		9.93			10.09
Finance leases		8.11			8.16

~~The maturity of the contractual undiscounted~~Future minimum lease ~~liabilities~~payments under our non-cancellable leases as of ~~September 30, 2021~~March 31, 2022 is as follows:


	Operating leases			Finance leases			Operating leases			Finance leases
	(dollars in thousands)						(in thousands)
Remainder of 2021	$	1,991		$	2,494
2022		8,173			10,509
Remainder of 2022							$	17,371		$	9,852
2023		7,886			13,246			22,465			15,930
2024		7,759			9,395			22,145			12,160
2025		7,800			9,069			21,792			11,747
2026								21,259			11,325
Thereafter		35,893			43,875			118,546			47,049
Total undiscounted lease liabilities		69,502			88,588			223,578			108,063
Interest on lease liabilities		(21,581	)		(26,000	)		(84,450	)		(31,991	)
Total present value of minimum lease payments		47,921			62,588			139,128			76,072
Lease liability - current portion		(4,264	)		(5,354	)
Lease liability	$	43,657		$	57,234
Lease liabilities- current portion								(10,553	)		(6,905	)
Lease liabilities							$	128,575		$	69,167

NOTE 13. CONSTRUCTION FINANCE LIABILITIES

~~During the third quarter of 2021, the Company identified a misstatement in its accounting for leases in prior periods, primarily the second quarter of 2021. Refer to "~~Holyoke~~Note 2. Basis of Presentation" under "Revisions of Previously Issued Financial Statements" above for additional details.~~

~~NOTE~~ ~~11. CONSTRUCTION FINANCE LIABILITIES~~

In July 2019, the Company sold property it had recently acquired in Massachusetts for $3.5 million, which was the cost to the Company. In connection with the sale of this location, the Company agreed to lease the location back for cultivation. This transaction was determined to be a finance lease, and therefore did not meet the definition of a sale because control was never transferred to the buyer-lessor. The transaction was treated as a failed sale-leaseback financing arrangement.

Included in the agreement, the Company completed the tenant improvements related to the property, for which the landlord has ~~agreed to provide~~provided a tenant improvement allowance (“TI Allowance”) offor $40.0 ~~million, which was dispensed in its entirety as~~million. As of December 31, ~~2020.~~2021, the entire TI Allowance had been provided. The initial term of the agreement is ten years, with 2 five-yearoptions to ~~extend the term for~~ ~~five years~~ ~~each.~~renew. The initial payments are equal to 11% of the sum of the purchase price for the property and will increase when a draw is made on the TI Allowance. In addition, a 3% increase in payments will be applied annually after the first year. As of ~~September 30,~~March 31, 2022, and December 31, 2021, the total finance liability associated with this transaction is $~~44.4~~44.8 ~~million.~~million and $44.6 million, respectively.

Ben Bostic

In October 2019, the Company sold property in Florida in exchange for cash of $17.0 million. Concurrent with the closing of the purchase, the buyer entered into a lease agreement with the Company, for continued operation as a licensed medical cannabis cultivation facility. Control was never transferred to the buyer-lessor because the transaction was determined to be a finance lease and did not meet the requirements of a sale. The transaction was treated as a failed sale-leaseback financing arrangement.

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

The initial term of the agreement is ten years, with 2 five-yearoptions to ~~extend the term for~~ ~~five years~~ ~~each.~~renew. The initial annualized payments are equal to 11% of the purchase price for the property. A 3% increase in payments will be applied annually after the first year. As of ~~September 30,~~March 31, 2022, and December 31, 2021, the total finance liability associated with this transaction is $17.5 million and $17.4 ~~million.~~million, respectively.

McKeesport

In October 2019, prior to ~~its~~ acquisition by the Company, PurePenn, ~~LLC (“PurePenn”)~~ sold their cannabis cultivation facility in Pennsylvania for $5.0 million. Simultaneously with the closing of the sale, PurePenn agreed to lease the cultivation facility back. The transaction was treated as a failed sale-leaseback financing arrangement.

The initial term of the lease is ~~fifteen years~~15, years, with 2 five-year options to renew. The landlord has agreed to provide a TI ~~allowance~~Allowance of $21.0 million as an additional component of base rent. Payments are made based on one twelfth (1/12)of the TI allowance dispersed with 12.75% due for the first $5.0 million, 13.25% for $5.0 million to $15.0 million and ~~13.75~~13.50% ~~thereafter. On March 8,~~for $15.0 to $21.0 million. In 2021, the Company entered into ~~a lease~~an amendment with the landlord to increase the tenant improvement allowance toby an additional $15.5 million for a total of $36.5 million at a rate of 10.75% on the additional allowance in excess of $21.0 million. As of ~~September 30,~~March 31, 2022, and December 31, 2021, $~~25.6~~29.5 million and $29.5 million of the TI allowance has been ~~provided.~~provided, respectively.

Alachua

In October 2021, in connection with the acquisition of Harvest, the Company acquired a transaction in which Harvest sold a licensed cultivation and processing facility and simultaneously with the closing of the sale, agreed to lease the facility back. The transaction was treated as a failed sale-leaseback financing arrangement.

The initial term of the lease is 20 years, with 2five-year options to renew. The landlord has agreed to provide a TI Allowance of $17.9 million as an additional component of base rent. As of ~~September 30,~~March 31, 2022, and December 31, 2021, ~~the total finance liability associated with this transaction is~~ $~~30.2~~17.9 ~~million.~~million and $15.3 million of the TI allowance has been provided, respectively.

In the first quarter of 2022, the Company temporarily idled this facility. The Company is evaluating the future use of this facility and remains in compliance with the associated lease obligation.

Hancock

The initial term of the lease is ten years with 2options to extend the term the first providing a ten-year renewal option and the second providing a five-year renewal option. The landlord has agreed to provide a TI Allowance of $12.9 million as an additional component of base rent. As of March 31, 2022, and December 31, 2021, $10.5 million and $5.7 million of the TI allowance has been provided, respectively.

Under the ~~failed-sales-leaseback~~failed-sale-leaseback accounting model, the Company is deemed ~~under U.S. GAAP~~ to own ~~the above mentioned~~this real estate ~~properties as financing arrangements since control was never transferred to~~and will reflect the ~~buyer-lessor. These agreements are presented~~properties on our condensed consolidated balance sheet ~~within property~~ and ~~equipment, net and depreciated~~depreciate over the assets' remaining useful life.

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

Future minimum lease payments for the construction finance liabilities as of March 31, 2022, are as follows:


	(in thousands)
Remaining 2022	$	17,068
2023		23,406
2024		23,737
2025		24,176
2026		24,595
Thereafter		427,860
Total future payments		540,842
Less: Interest		(364,656	)
Total present value of minimum payments		176,186
Construction finance liabilities - current portion		(1,154	)
Construction finance liabilities	$	175,032

NOTE ~~13.~~15. SHARE-BASED COMPENSATION

Equity Incentive Plans

The Company’s 2021 Omnibus Incentive Plan (the “2021 Plan”) was adopted in June 2021 at the 2021 annual meeting of shareholders. The 2021 Plan reserves 4,000,000 Subordinate Voting Shares for issuance thereunder and replaced the Schyan Exploration Inc. Stock Option Plan (the “Prior Plan”). Awards previously granted under the Prior Plan, including equity awards granted in the first quarter of 2021 for performance in 2020, remain subject to the terms of the Prior Plan. NaN further grants of awards shall be made under the Prior Plan. The Prior Plan is administered by the Board of Directors of the Company and the 2021 Plan is administered by the Compensation Committee. The 2021 Plan provides for the grant of Incentive Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Shares, Performance Share Units, and Other Awards. ~~As of September 30, 2021 a total of~~ ~~895,877~~

~~awards were granted~~

Options

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

On January 4, 2022 and February 24, 2022, under the 2021 Plan, ~~between~~ the ~~date~~Board awarded options to purchase shares to board members, directors, officers, and key employees of ~~its adoption by shareholders on June 10, 2021~~the Company. The options granted vest immediately for board members and ~~September 30, 2021.~~all other options granted vest over a two-to three-year period.

~~Options~~

On October 26, 2021, under the 2021 Plan, the Board awarded options to purchase shares to officers and other select employees of the Company. The ~~fair value~~options generally vest over a two-to three-year period.

On October 1, 2021, the Company acquired Harvest which included consideration in the form of1,266,641 stock options ~~granted by~~(as converted) that had been issued before the ~~Company during~~acquisition date to employees and non-employees of Harvest. The post-combination options vest over a one-to three-year period.

On September 29, 2021, under the 2021 Plan, the Board awarded options to purchase shares to officers and ~~2020,~~other select employees of the Company. The September 29, 2021, options vest over a three-year period.

On January 4, 2021, under the Prior Plan, ~~were estimated on~~ the ~~date~~Board awarded options to purchase shares to directors, officers, and key employees of the ~~grant using~~Company. The January 4, 2021, options generally vest over a two-to three-year period.

In determining the amount of share-based compensation related to options issued during the periods ending March 31, 2022 and 2021, the Company used the Black-Scholes ~~option-pricing~~pricing model to establish the fair value of the options granted with the ~~relevant assumptions outlined in the table below.~~ following assumptions:


	For the Three Months Ended March 31, 2022	For the Three Months Ended March 31, 2021
Fair value at grant date	$8.39-11.01	$11.20
Stock price at grant date	$21.48-$25.41	$33.42
Exercise price at grant date	$21.48-$25.41	$33.42
Expected life in years	3.50 - 4.46	3.00
Expected volatility	51.81% - 52.87%	49.88%
Expected annual rate of dividends	0%	0%
Risk free annual interest rate	1.20% - 1.79%	0.11%

The expected volatility was estimated by using the historical volatility of the Company. In cases where there is insufficient trading history, the expected volatility is estimated using the historical volatility of other companies that the Company considers comparable that have trading and volatility history prior to the Company becoming public. The expected life in years represents the period of time that options granted are expected to be ~~outstanding.~~outstanding and is computed using the simplified method. The risk-free rate was based on the United States~~three-year~~ bond yield rate at the time of grant of the award. Expected annual rate of dividends is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

On January 3, 2020, under the Prior Plan, the Board awarded options to purchase shares to directors, officers, and key employees of the Company. In accordance with the Prior Plan’s policy, the vesting period for employees is 15~~% as of the date of issuance,~~ 25~~% vested on December 31, 2020, and~~ 60~~% vest on December 31, 2021. For founding members of the Board of Directors, the options were fully vested on the date of grant. For non-founding members of the Board of Directors,~~ 50~~% of the options were vested on December 31, 2020, and~~ 50~~% will vest on December 31, 2021.~~

~~On January 4, 2021, under~~For the ~~Prior Plan, the Board awarded options to purchase shares to directors, officers, and key employees of the Company. In accordance with the Prior Plan’s policy, the vesting period for employees is~~ 15~~% vest on December 31, 2021,~~ 25~~% vest on December~~three months ended March 31, 2022, and60~~% vest on December 31, 2023. For founding and non-founding members of the Board of Directors,~~ 50~~% of the options vest on December 31, 2021, and~~ 50~~% will vest on December 31, 2022.~~

~~On September 29, 2021, under the 2021 Plan, the Board awarded options to purchase shares to officers and other select employees of the Company. The options vest over~~ ~~three years~~ ~~and have a contractual term between~~ ~~six~~ ~~and~~ ~~seven years~~. ~~In accordance with the 2021 Plan’s policy, the vesting period for directors and officers is~~ ~~33 1/3% vest on December 1, 2021,~~ ~~33 1/3% vest on December 1, 2022, and~~ ~~33 1/3% vest on December 1, 2023.~~

For the Nine Months Ended September 30, 2021
For the Nine Months Ended September 30, 2020
Fair value at grant date
$10.58-$11.20
$3.11-$3.26
Stock price at grant date
$26.88-$33.42
$11.52-$12.50
Exercise price at grant date
$26.88-$33.42
$11.52-$12.50
Expected life in years
3.00 - 3.50
1.58 - 2.00
Expected volatility
49.88% - 53.75%
49.10% - 50.15%
Expected annual rate of dividends
0%
0%
Risk free annual interest rate
0.16% - 0.79%
1.40 - 1.58%

~~For the nine months ended September 30,~~ 2021, the Company recorded share-based compensation for all stock options in the amount of $2.2 ~~million.~~million and $0.7 million, respectively. This is recognized as $~~0.2~~0.1 million and $0.1 million, cost of goods sold, ~~net,~~ $~~1.6~~1.7 million and $0.5 million general and administrative, and $~~0.4~~0.3 million and $0.1 million, sales and marketing in the condensed consolidated statements of operations and comprehensive (loss) income.

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

The ~~number and weighted-average exercise prices and remaining contractual life~~following is a summary of ~~options at September 30, 2021 were as follows:~~stock option activity:


	Number of options			Weighted average exercise price		Weighted average remaining contractual life (yrs)		Aggregate intrinsic value		Number of options			Weighted average exercise price		Weighted average remaining contractual life (yrs)		Aggregate intrinsic value
Outstanding at January 1, 2021		1,129,774			11.72		4.01		—
Outstanding, January 1, 2022											2,973,895		$	27.61		6.26	$	—
Granted		877,509			29.32		3.55		—		864,051			21.56
Exercised		(36,787	)		11.52		—		—		(88,278	)		11.32
Forfeited		—			—		—		—		(121,127	)		55.93
Outstanding, September 30, 2021		1,970,496		$	19.56		4.52	$	8.43
Exercisable, September 30, 2021		517,672		$	11.71		3.34	$	15.20
Outstanding, March 31, 2022											3,628,541		$	25.62		6.23	$	—
Exercisable, March 31, 2022											1,569,874		$	18.21		3.70	$	2.84


	Number of options		Weighted average exercise price		Weighted average remaining contractual life (yrs)		Aggregate intrinsic value
Outstanding at January 1, 2021		1,129,779	$	11.72		4.01	$	19.90
Granted		326,867		33.42
Exercised		—		—
Forfeited		—		—
Outstanding, March 31, 2021		1,456,646	$	16.59		4.05	$	28.91
Exercisable, March 31, 2021		554,459	$	11.70		3.84	$	33.80

~~Total unvested options as~~As of ~~September 30, 2021, are~~ March 31, 2022, there was approximately $~~1,452,824~~12.7 ~~which are expected to vest over time and have an aggregate~~million of unrecognized compensation ~~expense of $8.5~~ ~~million. The unrecognized compensation expense will~~cost related to nonvested stock option arrangements which is expected to be recognized over a weighted average period of ~~2.09~~0.91 years.

~~As noted above, following shareholder approval of the 2021 Plan,~~ 0 ~~further grants of awards shall be made under the Prior Plan.~~

Restricted Stock Units

Restricted stock units ("RSUs") represent a right to receive a single Subordinate Voting Share that is both non-transferable and forfeitable unless and until certain conditions are satisfied. RSUs vest ratably over a two to three year period subject to continued employment through each anniversary. The fair value of RSUs is determined on the grant date and is amortized over the vesting period on a straight-line basis.

On January 4, February 24, and March 31, 2022, the Board awarded RSUs to board members, directors, officers, and key employees of the Company. The RSUs vest immediately for board members and all other RSUs granted vest over a two-year period.

On September 15, 2021, the Board awarded RSUs to2 officers of the Company as replacement awards for cancelled warrants, which vest immediately. ~~On September 29, 2021, under the 2021 Plan, the Board awarded RSUs to officers, and other select employees of the Company, which vest over a~~ ~~two~~ to ~~three year~~ ~~period.~~

Number of
restricted stock units

Weighted average
grant price

Balance as of January 1, 2021

—

—

Granted

3,249,319

25.45

Vested

(2,904,079
)

25.28

Forfeited

—

—

Balance as of September 30, 2021

345,240

$
26.88

~~NaN~~ ~~share-based compensation expense was recorded for RSUs during the three months ended September 30, 2021.~~

~~In September 2021, the Board of Directors approved grants of RSUs for~~ 2 ~~executive officers who~~The previously held ~~warrants. The previously held~~3,572,514 warrants were cancelled on September 15, 2021 with the new RSUs granted on September 15, 2021 as a replacement of the previously held warrants. The 2 officers were awarded a total premium of $3.1 million, allocated between the 2 officers, to incentivize the cancellation and ~~replacement.~~ ~~NaN~~ ~~share-based compensation expense~~replacement, which was recorded ~~related~~ to general and administrative expenses in the ~~cancellation~~consolidated statements of operations and ~~replacement~~comprehensive (loss) income.

On September 29, 2021, under the 2021 Plan, the Board awarded RSUs to officers and other select employees of the ~~previous warrants with the new RSUs during~~Company, which vest over a two-to three-year period.

Trulieve Cannabis Corp.

Notes to Condensed Consolidated Financial Statements

The following is a summary of RSU activity:


	Number of restricted stock units			Weighted average grant price
Unvested balance as of January 1, 2022		332,428		$	26.86
Granted		821,800			21.51
Vested		(24,444	)		21.48
Forfeited		(51,460	)		26.00
Unvested balance as of March 31, 2022		1,078,324		$	22.94

During the three months ended ~~September 30, 2021.~~March 31, 2022, the Company recorded share-based compensation in the amount of $2.4 million related to RSUs. This is recognized as $0.2 million cost of goods sold, $1.9 million general and administrative and $0.3 million sales and marketing in the statements of operations and comprehensive (loss) income.

As of March 31, 2022, there was approximately $21.5 million of total unrecognized compensation cost related to unvested restricted stock units which is expected to be recognized over a weighted-average service period of 1.11 years.

Warrants

During the year ended December 31, 2018, the Company issued 8,784,872 warrants to certain employees and directors of the Company for past services provided. The warrants had 0 vesting conditions and are exercisable at any time for three years after the issuance, subject to certain lock-up provisions:(i) the warrants may not be exercised for 18 months following the Issue Date; (ii) 50% of the warrants may be exercised between months 19-24 following the Issue Date; and (iii) the remaining 50% of the warrants may be exercised

at any time thereafter until expiration. The warrants are exchangeable into Subordinate Voting Shares. ~~For the nine months ended September 30, 2021 and 2020,~~ 0 ~~warrants related to share-based compensation were issued. As the warrants had no vesting conditions, the entire share-based compensation expense of $15.0~~ ~~million was recognized when the warrants were issued in 2018.~~

The following table summarizes the activity related to warrants issued and outstanding to certain employees and directors of the Company for the three month period ending March 31, 2021. There were 0 outstanding warrants as of December 31, ~~2020~~2021 and ~~the~~no changes to outstanding warrants occurred during the ~~nine~~three months ended ~~September 30, 2021:~~March 31, 2022.

Number of warrants

Weighted average exercise price ($CAD)

Weighted average remaining contractual life (yrs)

Outstanding as of January 1, 2021

6,061,561

6.00

0.72

Granted

—

—

—

Exercised

(2,075,990
)

6.00

—

Exchanged in cashless exercise

(413,057
)

—

—

Cancelled

(3,572,514
)

—

—

Outstanding as of September 30, 2021

—

—

—


	Number of warrants			Weighted average exercise price ($CAD)		Weighted average remaining contractual life (yrs)
Outstanding, December 31, 2020		6,061,561			6.00		0.72
Granted		—			—		—
Exercised		(133,408	)		—		—
Forfeited		(16,592	)		—		—
Outstanding, March 31, 2021		5,911,561			6.00		0.48

Notes to ~~the restricted stock unit disclosure above for additional information regarding the issuance of RSU's in exchange for the cancelled warrants held by~~ 2 ~~executive officers.~~Condensed Consolidated Financial Statements

For the three months ended March 31, 2022, the Company excluded 3,628,541 options, 1,078,324 RSUs, and 3,636,029 warrants, from the dilutive calculation as the Company is in a net loss position. For the three months ended March 31, 2021, the Company excluded 926,242 options from the dilutive calculation as they would have been anti-dilutive. For the three months ended March 31, 2021, the Company excluded 619,237 warrants as they would have been anti-dilutive. As of March 31, 2022, there are approximately 184 million issued and outstanding shares which excludes approximately 2.9 million of fully vested RSUs which are not contractually issuable until 2024.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and accompanying notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our ~~2020~~2021 Form 10-K. This discussion contains forward-looking statements and involves numerous risks and uncertainties, including but not limited to those described in the “Risk Factors” section of this Quarterly Report on Form 10-Q and in “Part I, Item 1A—Risk Factors” in our ~~2020~~2021 Form ~~10-~~K.10-K. Actual results may differ materially from those contained in any forward-looking statements. You should read “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” contained herein and in our ~~2020~~2021 Form 10-K.

We are a vertically integrated cannabis company and multi-state ~~cannabis~~ operator ~~with~~which currently holds licenses to operate in ~~six~~ten states and ~~we have~~has received notice of intent to award a license in ~~a seventh state.~~an eleventh state. Headquartered in Quincy, Florida, we are the market leader for quality medical cannabis products and services in Florida and we have market leading retail operations in Arizona and Pennsylvania. By providing innovative, high-quality products across our brand portfolio, we aim to be the brand of choice for medical and adult-use customers in all of the markets that we serve. We operate in highly regulated markets that require expertise in cultivation, manufacturing, retail and logistics. We have developed proficiencies in each of these functions and are committed to expanding access to high quality cannabis products and delivering exceptional customer experiences.

All of the states in which we operate have adopted legislation to permit the use of cannabis products for medicinal purposes to treat specific conditions and diseases, which we refer to as medical cannabis. Recreational marijuana, or adult-use cannabis, is legal marijuana sold in licensed dispensaries to adults ages 21 and older. Thus far, of the states in which we operate, only Arizona, California, Colorado, Connecticut, Massachusetts and ~~Massachusetts~~Nevada have adopted legislation permitting commercialization of adult-use cannabis products. As previously disclosed, on October 1, 2021, we completed our previously announced acquisition of Harvest Health & Recreation Inc. (“Harvest”) and, as a ~~result~~result of the acquisition, our operations have expanded significantly effective as of such date. As of May 2, 2022, we operated 165 dispensaries, with 115 dispensaries in Florida, 19 affiliated dispensaries in Pennsylvania, 17 dispensaries in Arizona, five dispensaries in California, three dispensaries in Maryland, three dispensaries in Massachusetts, two dispensaries in West Virginia and one dispensary in Connecticut, and we operated cultivation and processing facilities in Arizona, Colorado, Florida, Maryland, Massachusetts, Nevada, Pennsylvania, and West Virginia.

As of ~~September 30, 2021,~~March 31, 2022, we employed over ~~6,900~~9,000 people, and we are committed to providing patients and adult consumers, which we refer to herein as ~~“patients” or~~ “customers,” a consistent and welcoming retail experience across Trulieve branded stores. We have nine material subsidiaries: Trulieve, Inc., or Trulieve US; Leef Industries, LLC, or Leef Industries; Life Essence, Inc., or Life Essence; Trulieve Holdings, Inc., or Trulieve Holdings; Trulieve Bristol, Inc. (formerly The Healing Corner, Inc.) or Healing Corner; PurePenn LLC, or PurePenn; Keystone Relief Centers, LLC or Solevo Wellness; Trulieve WV, Inc., or Trulieve WV;stores and Trulieve GA, Inc., or Trulieve GA. Each of Trulieve US, Leef Industries, Life Essence, Trulieve Holdings, Healing Corner, PurePenn LLC, Solevo Wellness and Trulieve WV is wholly owned (directly or indirectly) by Trulieve Cannabis Corp. Trulieve GA is 40% owned (indirectly) by Trulieve Cannabis Corp.affiliated retail locations. As of ~~September 30, 2021,~~March 31, 2022, the majority of our revenue was generated from the sale of medical cannabis products in the State of Florida and into a lesser extent Arizona and the Commonwealth of Pennsylvania. To date, neither the sale of adult-use cannabis products, nor our operations in ~~Massachusetts,~~ California, Connecticut, Colorado, Maryland, Massachusetts, Nevada, or West Virginia, have been material to our business.

Our business and operations center around the Trulieve brand philosophy of “Customers First” which permeates our culture beginning with high- quality and efficient cultivation and manufacturing practices, focus on the consumer experience at Trulieve branded and affiliated retail locations, at our in-house call center and where available at customer residences through a robust home delivery program. Our investments in vertically integrated operations in several of our markets afford us ownership of the entire supply chain which mitigates third-party risks and allows us to completely control product quality and brand experience. We believe that this contributes to high customer retention and brand loyalty. We successfully operate our core business functions of cultivation, production and distribution at scale, and are skilled at rapidly increasing capacity without any interruption to existing operations.

Trulieve ~~US is a vertically integrated “seed to sale” cannabis company and is the largest licensed medical marijuana company~~has identified five regional geographic hubs in the ~~State~~U.S. and has established cannabis operations in three of the five hubs: Southeast, Northeast, and Southwest. In each of our three regional hubs we have market leading positions in cornerstone states and additional operations and assets in other state markets. Our hubs are managed by national and regional management teams supported by our corporate headquarters in Florida.

Our southeast hub operations are anchored by our cornerstone market of Florida. ~~As of September 30, 2021, publicly~~Trulieve was the first licensed operator in the medical market in Florida with initial sales in 2016. Publicly available reports filed with the Florida Office of Medical Marijuana Use show Trulieve ~~US to have~~has the most dispensing locations and the greatest dispensing volume across product categories out of all licensed medical marijuana businesses in the ~~state.~~state as of December 31, 2021. Trulieve US cultivates and produces all of its products in-house and distributes those products to ~~patients~~customers in Trulieve branded stores (dispensaries) throughout ~~the State of~~ Florida, as well as ~~directly to patients~~ via home delivery. Our experience in the vertically integrated Florida market has given us the ability to scale and penetrate in all necessary business segments (cultivation, production, sales, and distribution). Trulieve US has the experience necessary to increase market leadership in Florida and employ that expertise effectively in other regulated markets.

As of ~~September 30, 2021,~~March 31, 2022, Trulieve US operated ~~approximately~~ ~~2.2 million square feet of~~ cultivation and processing facilities across ~~six sites.~~thirteen sites and 113 retail dispensaries throughout the state. In accordance with Florida law, Trulieve US grows all of its cannabis in secure enclosed indoor facilities and greenhouse structures.

~~Life Essence operates~~ In furtherance of our customer-first focus, we have developed a ~~co-located medical~~suite of Trulieve branded products, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and ~~adult-use dispensaries~~nasal sprays. This wide variety of products gives customers the ability to select the product that consistently delivers the desired effect and in Northampton and Worcester and Medical Marijuana cultivation and product manufacturing facility in Holyoke. Life Essence also has been awarded Final Licenses for Adult-Use cultivation and processing at the same facility in Holyoke, and provisional certificatestheir preferred method of registration for medical marijuana dispensaries in Holyoke and Cambridge. Upon entry of its existing plant stock into the state’s seed to sale tracking system and clearance from the Massachusetts Cannabis Control Commission, Life Essence ~~became fully operational in the third quarter of 2021,~~ ~~under its adult-use cultivation and processing licenses, including in the wholesale market. The completion of these licensing processes will further enable Life Essence to~~delivery.

~~capitalize on its investment in infrastructure and engage in vertically integrated operations in both adult-use and medical markets in Massachusetts.~~

On July 2, 2021, Life Essence closed a transaction with Patient Centric of Martha’s Vineyard Ltd., or PCMV, in which Life Essence purchased certain assets of PCMV, including the rights to a Provisional Marijuana Retailer License from the Massachusetts Cannabis Control Commission in Framingham, Massachusetts, and necessary municipal entitlements and a leasehold interest to operate as a marijuana retailer at the property. On June 29, 2021, Life Essence closed a transaction with Nature’s Remedy of Massachusetts, Inc., or Nature’s Remedy, and Sammartino Investments, LLC, pursuant to which Life Essence agreed to purchase certain assets of Nature’s Remedy including a Final Marijuana Retailer License from the Cannabis Control Commission, assignment of a long-term lease for real property in Worcester, Massachusetts for use as a marijuana retailer, and necessary municipal entitlements to operate as a marijuana retailer at the property. Following a satisfactory post final license inspection from the Massachusetts Cannabis Control Commission, this marijuana retailer location in Worcester, Massachusetts commenced operations in August 2021.

~~Leef Industries operates a licensed medical and adult-use cannabis dispensary located in Palm Springs, California.~~In Georgia, Trulieve believes Leef Industries has demonstrated encouraging growth in the market, offering in-store and online shopping, along with product home delivery. Leef Industries is in the process of Trulieve rebranding and alignment with corporate operational standards, which we believe will increase consumer appeal and operational efficiency. The dispensary helps us stay abreast of trends on the west coast and in a robust and innovative cannabis market distinguished by local competition between diverse and numerous operators.

Healing Corner is a licensed pharmacist-managed medical cannabis dispensary located in Bristol, Connecticut. Healing Corner was founded in 2014 and provides a range of medical marijuana products produced by high quality licensed suppliers. At the dispensary, a licensed pharmacist and trained staff provide on-site counseling and education to patients. Patients may reserve their medical marijuana order through Healing Corner’s innovative Canna-Fill online system. Under Connecticut’s adult-use cannabis legislation, which was enacted July 1, 2021, Healing Corner will have an opportunity to convert to hybrid adult-use and medical sales.

On November 12, 2020, we completed the acquisition of 100% of the membership interests of: (i) PurePenn LLC and Pioneer Leasing & Consulting LLC, which we refer to collectively as PurePenn, and (ii) Keystone Relief Centers, LLC, which does business as and we refer to herein as Solevo Wellness. PurePenn operates cannabis cultivation and manufacturing facilities in the Pittsburgh, Pennsylvania area and currently wholesales to 100% of the operating dispensaries in Pennsylvania. Solevo Wellness operates three medical marijuana dispensaries in the Pittsburgh, Pennsylvania area. On July 8, 2021, we completed the acquisition of 100% of the membership interest of Anna Holdings LLC, which does business as Keystone Shops and operates three dispensaries in the Philadelphia area.

On November 13, 2020, Trulieve WV was awarded a processor permit by the West Virginia Office of Medical Cannabis. On January 29, 2021, Trulieve WV was notified that it has been awarded four dispensary permits by the West Virginia Office of Medical Cannabis. On March 22, 2021, we entered into a membership interest purchase agreement with Mountaineer Holding, LLC (“Mountaineer”). Mountaineer holds a West Virginia cultivation license and two dispensary licenses. The acquisition of Mountaineer was completed on May 5, 2021. On June 8, 2021, we completed the acquisition of Solevo Wellness West Virginia LLC and its three West Virginia dispensary permits. On June 29, 2021, we received approval from the West Virginia Office of Medical Cannabis to begin cultivation operations, making Trulieve the first in the state of West Virginia to begin cultivating medical cannabis. We are actively working to obtain approval for processing and dispensing operations as soon as reasonably practicable, which will vary by location depending on permitting and construction timelines.

~~On July 24, 2021, Trulieve GA~~ received a Notice of Intent to award a Class 1 Production License from the Georgia Access to Medical Cannabis ~~Commission.~~Commission in July 2021. The Notice of Intent to award is a notice of the Georgia Access to Medical Cannabis Commission’s expected contract award to Trulieve GA pending resolution of a protest process. If the contract is awarded, Trulieve GA will hold one of two Class 1 Production Licenses in the state and will be permitted to cultivate cannabis for the manufacture of low tetrahydrocannabinol, or THC oil.

On May 10, 2021, the Company entered into an Arrangement Agreement (the "Arrangement Agreement") with Harvest Health & Recreation Inc., a British Columbia corporation (“Harvest”), pursuant to which the Company agreed to acquire all of the issued and outstanding equity securities of Harvest. Under the terms of the Arrangement Agreement, shareholders of Harvest will receive 0.1170 of a Subordinate Voting Share of Trulieve for each Harvest subordinate voting share (or equivalent) held.

~~On October 1, 2021 (the "Closing Date"), the Company completed its previously announced acquisition~~Our northeast hub operations are anchored by our cornerstone market of Harvest pursuant to an Arrangement Agreement. On the Closing Date, the Company acquired all of the issued and outstanding subordinate voting shares, multiple voting shares and super voting shares (collectively the "Harvest Shares") of Harvest. Pursuant to the terms of the Arrangement Agreement, holders of Harvest Shares received 0.1170 of a Subordinate Voting Share of the Company for each subordinate voting share of Harvest held. In total, the Company issued an aggregate of 50,874,175 Trulieve Shares, representing total consideration of approximately $1.4 billion based on the closing price of Trulieve's Subordinate Voting Shares on September 30, 2021.Pennsylvania.

~~Prior~~We conduct cultivation, processing, and retail operations through its direct and indirect subsidiaries with permits for retail operations and grower/processor operations in Pennsylvania. These subsidiaries operate cultivation and processing facilities in McKeesport, Reading, and Carmichael, Pennsylvania to support our affiliated network of retail dispensaries and wholesale distribution network across the ~~acquisition, Harvest~~state.

We operate three medical dispensaries in Maryland and conduct wholesale sales supported by cultivation and processing in Hancock, Maryland. As of May 2, 2022, we operate three retail dispensaries in Massachusetts, serving medical and adult use customers in Northampton and adult use customers in Worcester and Framingham as of May 2, 2022. Our retail operations are supported by cultivation and manufacturing operations in Holyoke. We commenced wholesale sales in September 2021. Trulieve was ~~one~~the first to offer sales of ~~the largest multi-state vertically integrated operators~~clones supporting home grow for residents in the Massachusetts market in August 2021.

We operate a medical cannabis ~~industry~~dispensary located in ~~the United States operating from “seed~~Bristol, Connecticut. Under Connecticut’s adult-use cannabis legislation, which was enacted July 1, 2021, Trulieve can seek regulatory approval to ~~sale.” Harvest is one~~expand sales at this dispensary to include adult use sales.

We operate two medical dispensaries in Morgantown, and Weston, West Virginia, supported by cultivation and processing operations in Huntington, West Virginia. As of ~~the largest operators~~May 2, 2022, Trulieve has been awarded and has acquired permits to operate up to a total of ten dispensaries in ~~the state~~West Virginia.

Our southwest hub operations are anchored by our cornerstone market of Arizona. In Arizona, ~~which is one of the largest~~Trulieve holds a market-leading position, offering medical and ~~recreational cannabis~~adult use customers a wide range of branded and third-party products, including brand partner products. We also serve medical and adult use customers in California. Trulieve conducts wholesale operations in Nevada and Colorado, serving the medical and adult use markets in the country and one of the oldest regulated cannabis markets in the world. Harvest operates facilities or provides services to cannabis dispensaries in Arizona, California, Colorado, Florida, Maryland, Nevada, North Dakota (on February 19, 2021, Harvest completed the divestiture of its North Dakota retail assets), Pennsylvania and Utah, with two provisional licenses in Massachusetts. In addition, Harvest owns CO2 extraction, distillation, purification and manufacturing technology used to produce a line of cannabis topicals, vapes and gems featuring cannabinoids and a hemp-derived product line sold in Colorado. We expect the Harvest acquisition will have a significant impact on our results of operations and financial condition as of and for the fourth quarter ending December 31, 2021 and in future periods as we integrate Harvest’s business with our existing operations.each state.

On ~~October 6, 2021,~~January 28, 2022, the Company closed ~~its previously announced~~on a second tranche private placement of 8% Senior Secured Notes (the ~~"Notes"~~"2026 Notes") for aggregate gross proceeds of ~~$350.0 million and net proceeds of $342.6~~$75.6 million. The 2026 Notes ~~were issued~~bear interest at ~~100% face value, bear an interest~~a rate of 8% per annum, payable semi-annually in equal installments until the maturity date, unless earlier redeemed or repurchased. The 2026 Notes ~~will~~ mature on October 6, 2026, and may be redeemed in whole or in part, at the Company's option, at any ~~time from time to~~ time, on or after October 6, 2023, at the ~~application~~applicable redemption price set forth in the Indenture. The Company used a portion of the net proceeds to redeem certain outstanding indebtedness of Harvest, and intends to use the remaining portion of the net proceeds for capital expenditures and other general corporate purposes.

On September 29, 2021, the Board of Directors of the Company appointed Rebecca Young as Vice President and Chief Accounting Officer (and principal accounting officer) of the Company and its subsidiaries. Alex D'Amico, the Company's Chief Financial Officer and principal financial officer, will no longer serve as principal accounting officer of the Company.

Our management uses financial measures that are not in accordance with U.S. GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not aagreement.

27On February 14, 2022, the Company completed an acquisition whereby Trulieve acquired a cultivation operation from CP4 Group, LLC, in Phoenix, Arizona ("Watkins"). Total consideration was $27.5 million consisting of cash.

substitute for, our reported financial results prepared in accordance with GAAP. Adjusted EBITDA is a financial measure that is not defined under GAAP. Our management uses this non-GAAP financial measure and believes it enhances an investor’s understanding of our financial and operating performance from period to period because it excludes certain material non-cash items and certain other adjustments management believes are not reflective of our ongoing operations and performance. Adjusted EBITDA excludes from net income as reported interest, share-based compensation, tax, depreciation, acquisition and transaction costs, integration and transition costs, fair value step-up of inventory from acquisitions, COVID related expenses, non-cash expenses, other non-recurring costs and other income. Trulieve reports adjusted EBITDA to help investors assess the operating performance of the Corporation’s business. The financial measures noted above are metrics that have been adjusted from the GAAP net income measure in an effort to provide readers with a normalized metric in making comparisons more meaningful across the cannabis industry, as well as to remove non-recurring, irregular and one-time items that may otherwise distort the GAAP net income measure.

As noted above, our Adjusted EBITDA is not prepared in accordance with GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA rather than net income, which is the most directly comparable financial measure calculated and presented in accordance with GAAP. Because of these limitations, we consider, and you should consider, Adjusted EBITDA together with other operating and financial performance measures presented in accordance with GAAP. A reconciliation of Adjusted EBITDA from net income, the most directly comparable financial measure calculated in accordance with GAAP, has been included herein.

We derive our revenue from cannabis products which we manufacture, sell, and distribute to our customers by home delivery and in our dispensaries, as well as sales of cannabis products to wholesale customers in select markets.

Gross profit includes the costs directly attributable to product sales and includes amounts paid to produce finished goods, such as flower, and concentrates, as well as packaging and other supplies, fees for services and processing, allocated overhead which includes allocations of rent, administrative salaries, utilities, and related costs. Cannabis costs are affected by various state regulations that limit the sourcing and procurement of cannabis product, which may create fluctuations in margins over comparative periods as the regulatory environment changes.

Sales and marketing expenses consist primarily of personnel costs related to the dispensaries as well as marketing programs for our products. As we continue to expand and open additional dispensaries, we expect our sales and marketing expenses to continue to increase.

General and administrative expenses represent costs incurred at our corporate offices, primarily related to personnel costs, including salaries, incentive compensation, benefits, and other professional service costs, including legal and accounting. We expect to continue to invest considerably in this area to support our expansion plans and to support the increasing complexity of the cannabis business. Furthermore, we expect to continue to incur acquisition, transaction, and integration costs related to our expansion plans, and we anticipate a significant increase in compensation expenses related to recruiting and hiring talent, accounting, and legal and professional fees associated with becoming compliant with the Sarbanes-Oxley Act and other public company corporate expenses.

Depreciation expense is calculated on a straight-line basis using the estimated useful life of each asset. Estimated useful life is determined by asset class and is reviewed on an annual basis and revised if necessary. Amortization expense is recognized using the

straight-line method over the estimated useful life of the intangible assets. Useful lives for intangible assets are determined by type of asset with the initial determination of useful life derived during the valuation of the business combination. On an annual basis, the useful lives of each intangible class of assets are evaluated for appropriateness and adjusted if appropriate.

Other income (expense), net consist primarily of interest expense, interest income, loss on sale of non-operational assets, and ~~interest expense. Prior to December 10, 2020, the impact of~~ the revaluation of ~~the debt warrants was a significant component.~~derivative liabilities.

Provision for income taxes is calculated using the asset and liability method. Deferred income tax assets and liabilities are determined based on enacted tax rates and laws for the years in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

As we operate in the cannabis industry, we are subject to the limits of IRC Section 280E under which we are only allowed to deduct expenses directly related to the cost of producing the products or cost of production.

Revenue for the three months ended ~~September 30, 2021~~March 31, 2022 was ~~$224.1~~$318.3 million, an increase of ~~$87.8~~$124.5 million, from ~~$136.3~~$193.8 million for the three months ended ~~September 30, 2020. Revenue for the nine months ended September 30, 2021 was $633.0 million, an increase of $279.9 million, from $353.1 million for the nine months ended September 30, 2020.~~March 31, 2021. The increase in revenue is the result of an increase in organic growth in retail sales due to an

increase in products available for purchase and overall patient count, increased retail locations, as well as expansion of the wholesale business. ~~Between September 30, 2020~~During the period the Company made acquisitions such as Harvest and ~~September 30, 2021, we~~Keystone Shops, expanded business into new states such as Massachusetts and West Virginia, and opened ~~or acquired~~ ~~forty-two~~additional dispensaries w~~hich also contributed to the increased retail sales year over year. Revenue from businesses acquired also~~in existing markets such as Florida, all of which contributed to the increase ~~for the three and nine months ended September 30, 2021.~~in revenue.

Cost of goods sold for the three months ended ~~September 30, 2021~~March 31, 2022, was ~~$70.1~~$140.2 million, an increase of ~~$36.1~~$81.6 million, from ~~$34.1~~$58.6 million for the three months ended ~~September 30, 2020.~~March 31, 2021. Cost of goods sold ~~for the nine months ended September 30, 2021 was $199.3 million, an increase of $112.8 million, from $86.6 million for the nine months ended September 30, 2020,~~increased due to ~~an increase in retail sales as a result~~expansion of ~~an increase in dispensaries~~the business and ~~patient count.~~increased revenue. Cost of goods sold as a percentage of revenue increased from ~~25%~~30% for the ~~nine~~three months ended ~~September 30, 2020~~March 31, 2021, to ~~31%~~44% for the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 due to ~~our~~increased depreciation related to capital expenditures to support business growth, and expansion into new markets ~~ramping~~which are not fully vertical, resulting in the sale of ~~infrastructure in core markets,~~third party products, and ~~product mix.~~therefore yield lower margin than our vertical markets.

Gross profit for the three months ended ~~September 30, 2021~~March 31, 2022, was ~~$153.9~~$178.2 million, up ~~$51.8~~$42.9 million or ~~51%~~32% from ~~$102.2~~$135.3 million for the three months ended September 30, 2020. Gross profit for the nine months ended September 30, 2021 was $433.7 million, up $167.2 million or 63% from $266.5 million for the nine months ended September 30, 2020, as a result of an increase in retail sales due to the additional number of dispensaries, products available for sale and patient count.March 31, 2021. Gross profit as a percentage of revenue decreased from ~~75%~~70% for the ~~nine~~three months ended ~~September 30, 2020~~March 31, 2021, to ~~69%~~56%, for the ~~nine~~three months ended ~~September 30, 2021.~~March 31, 2022. The decrease is ~~caused by~~due to increased wholesale business which is generally lower margin than retail sales, increased depreciation related to capital expenditures to support business growth, and expansion into new markets ~~ramping~~which are not fully vertical, resulting in the sale of ~~infrastructure in core markets, product mix~~third party products, and ~~macro-economic factors centered around prices and labor.~~therefore yield lower margin than our vertical markets.

Sales and marketing expense increased by ~~67%~~64% from ~~$30.9~~$44.6 million for the three months ended ~~September 30, 2020~~March 31, 2021 to ~~$51.7~~$72.9 million for the three months ended September 30, 2021. Sales and marketing expense increased from $80.8 million for the nine months ended September 30, 2020 to $142.9 million for the nine months ended September 30, 2021, an increase of $62.1 million, or 77%.March 31, 2022. The increase in sales and marketing expense is the result of a higher headcount for the year, as we continue to add additional dispensaries in efforts to maintain and further drive higher growth in sales and market share as well as expanding into new markets. This increased headcount resulted in higher personnel costs, which is the primary driver for the increase year over year.

General and administrative expense for the three months ended ~~September 30, 2021~~March 31, 2022, increased by ~~232%~~164% to ~~$28.2~~$33.5 million from ~~$8.5~~$12.7 million for the three months ended September 30, 2020. General and administrative expense for the nine months ended September 30, 2021 increased to $55.9 million from $22.7 million for the nine months ended September 30, 2020, an increase of $33.2 million, or 146%.March 31, 2021. The increase in general and administrative expense is the result of entering new markets, ramping our infrastructure to support growth initiatives, continued acquisitions resulting in additional transaction and integration costs and increased go-forward compliance costs. General and administrative expenses included acquisition and transaction costs of ~~$11.1 million and $14.3~~$3.3 million for the three ~~and nine~~ months ended ~~September 30, 2021, respectively. Also included in the three and nine months ended September 30, 2021 is $4.2 million related to premiums on equity transactions.~~March 31, 2022.

Depreciation and amortization expense for the three months ended ~~September 30, 2021~~March 31, 2022, was ~~$7.7~~$29.3 million, up ~~$4.4~~$23.9 million from ~~$3.3~~$5.4 million for the three months ended September 30, 2020. Depreciation and amortization expenses for the nine months ended September 30, 2021 was $19.8 million, up $11.2 million, from $8.6 million for the nine months ended September 30, 2020.March 31, 2021. The overall increase in depreciation and amortization expenses was due to investment in infrastructure that resulted in a higher number of capitalized assets from the additional dispensaries and cultivation facilities. Furthermore, amortization expense increased due to acquisitions and acquired intangibles.

Loss on impairment and disposal of long-lived assets for the quarter ended March 31, 2022, increased to $13.8 million from zero for the three months ended March 31, 2021. The increase is primarily due to the write off of certain leases due to market changes in our Southeast hub and the disposal of certain long-lived assets.

Total other expense, net for the three months ended ~~September 30, 2021~~March 31, 2022, was expense of ~~$6.1~~$18.8 million, ~~a decrease~~an increase of ~~$10.1~~$10.9 million from expense of ~~$16.1~~$7.9 million for the three months ended September 30, 2020. Total other expense, net for the nine months ended September 30, 2021 was expense of $20.3 million, a decrease of $7.1 million from expense of $27.4 million for the nine months ended September 30, 2020.March 31, 2021. The overall ~~decrease~~increase is primarily the result of ~~the revaluation of debt warrants for the nine months ended September 30, 2020, partially offset by~~ an increase in interest expense related to additional finance leases to support business ~~growth.~~growth and loss on disposal of non-operational assets during the three months ended March 31, 2022.

On December 10, 2020, the Company entered into a Supplemental Warrant Indenture with Odyssey Trust Company pursuant to which it amended the terms of the issued and outstanding subordinate voting share purchase warrants of the Company (the “Public Warrants”) to convert the exercise price of the Public Warrants to $13.47 per share, the U.S. dollar equivalent of the Canadian dollar exercise price of the Public Warrants of C$17.25. As a result of this, the Public Warrants converted to equity in December 2020, eliminating revaluation expense in future periods.

Income tax expense for the three months ended ~~September 30, 2021~~March 31, 2022, increased to ~~$41.6~~$42.3 million from ~~$25.9~~$34.5 million for the three months ended September 30, 2020. Income tax expense for the nine months ended September 30, 2021 increased to $105.3 million from $67.1 million for the nine months ended September 30, 2020, an increase of $38.1 million, or 57% as a result of a $167.2 million increase in gross profit for the same periods.March 31, 2021. Under IRC Section 280E, cannabis companies are only allowed to deduct expenses that are directly related to production of the products. The Company's quarterly tax provision ~~and our quarterly estimate of our annual effective tax rate,~~ is subject to change resulting from several factors, including ~~variability in forecasting our pre-tax and taxable income due to external changes in market condition changes in statutes,~~ regulations and administrative practices, principles, and interpretations related to tax. The effective tax rate can be more or less volatile based on the amount of pre-tax income or loss. The impact of discrete items and non-deductible expenses on our effective tax rate is greater when our pre-tax income is lower. The increase in income tax expense is primarily due to the increase in gross profit as a result of ~~the increase in revenue as well as variability in the effective tax rate calculation which produced a large amount of tax expense in the quarter. The three months ended September 30, 2021, saw an~~ increased ~~tax expense as compared to prior periods due to variability in the effective tax rate.~~revenue.

Net ~~income~~loss for the three months ended ~~September 30, 2021~~March 31, 2022, was ~~$18.6~~$32.5 million ~~an increase~~a decrease of ~~$1.2~~$62.6 million, from ~~$17.4~~net income of $30.1 million for the three months ended ~~September 30, 2020. Net income for the nine months ended September 30, 2021 was $89.6 million, an increase of $29.6 million or 49%, from $60.0 million for the nine months ended September 30, 2020.~~March 31, 2021. The ~~increase~~decrease was driven primarily by the opening of additional dispensaries, an increase in products available for purchase, and overall patient count. These increases were offset by cost of goods sold which was driven by product mix. In addition, increases inlower gross margin, increased sales and marketing and general and administrative ~~expenses such as personnel~~ costs dispensary expenses, depreciation, interest expense, costs of entering new markets, ramping infrastructure, acquisition and transaction costs, integration costs, and go-forward compliance, all contributedrelated to the ~~offset. Income taxes also~~expanded organization, losses on disposal of long-lived assets, increased ~~period over period,~~other expense, and increased tax expense, as due to ~~both gross profit increases and effective~~the restrictions of 208E, the Company is not able to deduct many of their operating expenses for tax ~~rate variances.~~

Adjusted EBITDA for the three months ended September 30, 2021 was $98.0 million, an increase of $29.3 million from $68.7 million for the three months ended September 30, 2020. Adjusted EBITDA for the nine months ended September 30, 2021, was $283.7 million, an increase of $105.0 million or 59%, from $178.7 million for the nine months ended September 30, 2020. The following table presents a reconciliation of GAAP net income to non-GAAP Adjusted EBITDA, for each of the periods presented:

Since our inception, we have funded our operations and capital spending through cash flows from product sales, loans from affiliates and entities controlled by our affiliates, third-party debt, and proceeds from the sale of our capital stock. We are generating cash from sales and are deploying our capital reserves to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and long term to support our business growth and expansion. Our current principal sources of liquidity are our cash and cash equivalents provided by our operations and debt and equity offerings. Cash and cash equivalents consist primarily of cash on deposit with banks and money market funds. Cash and cash equivalents were ~~$213.6~~$267.2 million as of ~~September 30, 2021.~~March 31, 2022.

We believe our existing cash balances will be sufficient to meet our anticipated cash requirements from the report issuance date through at least the next twelve months.

Our primary uses of cash are for working capital requirements, capital expenditures and debt service payments. Additionally, from time to time, we may use capital for acquisitions and other investing and financing activities. Working capital is used principally for our personnel as well as costs related to the growth, manufacture, and production of our products. Our capital expenditures consist primarily of additional facilities and dispensaries, improvements in existing facilities and product development.

To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds. There can be no assurance that we will be able to obtain additional funds on terms acceptable to us, on a timely basis, or at all. The failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the results of operations and financial condition.

~~The following table presents our cash and outstanding debt as of the dates indicated:~~

Net cash provided by operating activities was ~~$75.1~~$45.1 million for the ~~nine~~three months ended ~~September 30, 2021, an increase~~March 31, 2022, a decrease of ~~$2.2~~$14.4 million, compared to ~~$72.8~~$59.6 million net cash provided by operating activities during the ~~nine~~three months ended ~~September 30, 2020.~~March 31, 2021. This is primarily due to ~~increased~~the current net loss versus net income ~~offset by~~in the prior year period, and increases in net working capital requirements, including inventory, as we ramp the business to support our growth.

Net cash used in investing activities was ~~$237.6~~$83.8 million for the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, an increase of ~~$146.8~~$30.5 million, compared to the ~~$90.8~~$53.4 million net cash used in investing activities for the ~~nine~~three months ended ~~September 30, 2020.~~March 31, 2021. The increase is primarily due to the ~~increase of property and equipment purchases for the construction of additional dispensaries and continued expansion of our cultivation and processing facilities, as well as acquisitions~~acquisition completed during the period.

Net cash provided by financing activities was ~~$229.4~~$72.2 million for the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, an increase of ~~$109.9~~$62.7 million, compared to the ~~$119.5~~$9.5 million net cash provided by financing activities for the ~~nine~~three months ended ~~September 30, 2020.~~March 31, 2021. The increase was primarily due to proceeds from the closing of ~~an underwritten, marketed public offering~~the second tranche of ~~5,750,000 Subordinate Voting Shares resulting in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by us, of $227.9 million (after giving effect to~~ the ~~conversion rate on April 7, 2021) as well as proceeds from share warrant exercises and proceeds from construction finance liabilities.~~Senior Secured Notes.

Private Placement Note Liabilities - “June Warrants” and “November Warrants”

On June 18, 2019, we completed an offering using our Canadian prospectus of 70,000 units (the “June Units”), comprised of an aggregate principal amount of US$70.0 million of 9.75% senior secured notes maturing in 2024 (the “June Notes”) and an aggregate amount of 1,470,000 subordinate voting share warrants (each individual warrant being a “June Warrant”) at a price of US$980 per June Unit for gross proceeds of US$68.6 million. Each June Unit was comprised of one June Note issued in denominations of $1,000 and 21 June Warrants.

On November 7, 2019, we completed an offering using our Canadian prospectus of 60,000 units (the “November Units”), comprised of an aggregate principal amount of US$60.0 million of 9.75% senior secured notes maturing in 2024 (the “November Notes”) and an aggregate amount of 1,560,000 subordinate voting share warrants (each individual warrant being a “November Warrant”) at a price of US$980 per November Unit for gross proceeds of US$61.1 million. Each November Unit was comprised of one November Note issued in denominations of $1,000 and 26 November Warrants.

On October 6, 2021, the Company closed on a ~~12% annual~~private placement of 8% Senior Secured Notes (the "“Notes") for aggregate gross proceeds of $350.0 million and net proceeds of $342.6 million. The Notes were issued at 100% face value, bear an interest rate ~~which was amended~~of 8% per annum payable semi-annually in ~~January 2019 to extend~~equal installments until the maturity ~~by three years~~date, unless earlier redeemed or repurchased. The Notes mature on October 6, 2026 and may be redeemed in whole or in part, at any time from time to 2022. The balance of these notes is $4.0 million. On December 17, 2017, we entered into a promissory note with a 12% annual interest rate and a balance of $2.0 million, which will mature December 2021. These notes were paidtime, on or after October 6, 2023 at the applicable redemption price set forth in the ~~fourth quarter~~trust indenture dated as of ~~2021.~~June 18, 2019 (the “Base Indenture”), as supplemented by a supplemental trust indenture dated as of October 6, 2021 (the “Supplemental Indenture” and, the Base Indenture as supplemented by the Supplemental Indenture, the “Indenture”), by and between the Company and Odyssey Trust Company, as trustee. The Company used a portion of the net proceeds to redeem certain outstanding indebtedness of Harvest, and intends to use the remaining net proceeds for capital

expenditures and other general corporate purposes. The Indenture governing the Notes contains covenants that, among other things, limit the ability of the Company and its restricted subsidiaries to, among other things, declare or pay dividends or make certain other payments; purchase, redeem or otherwise acquire or retire for value any equity interests or otherwise make any restricted payments; conduct certain asset sales or consolidate, merge or transfer all or substantially all of the assets of the Company and its subsidiaries on a consolidated basis; make certain restricted investments, incur certain indebtedness or grant certain liens, or enter into certain affiliate transactions. These covenants are subject to a number of other limitations and exceptions as set forth in the Indenture.

On January 28, 2022, the Company closed on a ~~24-month unsecured loan with~~second tranche private placement of 8% Senior Secured Notes for aggregate gross proceeds of $75.6 million. The Notes bear an ~~8% annual~~ interest rate ~~with Benjamin Atkins, a former director~~of 8% per annum payable semi-annually in equal installments until the maturity date, unless earlier redeemed or repurchased. The Notes will mature on October 6, 2026, and ~~shareholder of Trulieve for $257,337. In March 2018,~~may be redeemed in whole or in part, at the ~~Company entered into a 24-month unsecured loan with an 8% annual interest rate with Benjamin Atkins for $158,900. In June 2018,~~Company's option, at any time, on or after October 6, 2023, at the ~~Company entered into a 24-month unsecured loan with an 8% annual interest rate with Benjamin Atkins for $262,010. In November 2018,~~application redemption price set forth in the Company entered into two separate 24-month unsecured loans each with an 8% annual interest rate with a former director and shareholder for a total of $474,864. As of the first quarter-ended March 31, 2021, all loans with Benjamin Atkins have matured and been paid in full.Indenture.

In May 2018, the Company entered into two separate unsecured promissory notes (the “Traunch Four Note” and the “Rivers Note”) for a total of $12.0 million. The Traunch Four Note is held by Traunch Four, LLC, an entity whose direct and indirect owners include Kim Rivers, the Chief Executive Officer and Chair of the Board, as well as Thad Beshears, Richard May, who are each directors of Trulieve, George Hackney, a former director of Trulieve, and certain of Richard May’s family members. The Rivers Note is held by Kim Rivers. Each promissory note has a 24-month maturity and 12% annual interest rate. The two unsecured promissory notes were amended in March 2021 to extend the maturity one year to May 2022, all other terms remain unchanged. These notes were paid in the fourth quarter of 2021.

As of March 31, 2022, the entirety of our condensed consolidated balance sheet is exposed to U.S. cannabis-related activities. We believe our operations are in material compliance with all applicable state and local laws, regulations, and licensing requirements in the states in which we operate. However, cannabis remains illegal under U.S. federal law. Substantially all our revenue is derived from U.S. cannabis operations. For information about risks related to U.S. cannabis operations, please refer to the “Risk Factors” section of this Quarterly Report on Form 10-Q and "Part I, Item 1A - Risk Factors" in our ~~2020~~2021 Form 10-K.

As of March 31, 2022, we had the following contractual obligations to make future payments, representing contracts and other commitments that are known and committed:

As of the date of this filing, we do not have any off-balance-sheet arrangements that have, or are reasonably likely to have, a current or future effect on the results of operations or financial condition of, including, and without limitation, such considerations as liquidity and capital resources.

Our management uses financial measures that are not in accordance with generally accepted accounting principles in the U.S., or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Adjusted EBITDA is a financial measure that is not defined under GAAP. Our management uses this non-GAAP financial measure and believes it enhances an investor’s understanding of our financial and operating performance from period to period because it excludes certain material non-cash items and certain other adjustments management believes are not reflective of our ongoing operations and performance. Adjusted EBITDA excludes from net income as reported interest, provision for income taxes, and depreciation and amortization to arrive at EBITDA. This is then adjusted for items that do not represent the operations of the core business such as inventory step-up for fair value adjustments in purchase accounting, integration and transition costs, acquisition and transaction costs, other non-recurring costs, expenses related to the COVID-19 pandemic, impairments and disposals of long-lived assets, the results of entities consolidated as VIEs but not legally controlled and operated by the Company, and other income and expense items. Integration and transition costs include those costs related to integration of acquired entities and to transition major systems or processes. Acquisition and transaction costs relate to specific transactions such as acquisitions whether contemplated or completed and regulatory filings and costs related to equity and debt issuances. Other non-recurring costs includes miscellaneous items which are not expected to reoccur

frequently such as inventory adjustments related to specific issues and unusual litigation. Adjusted EBITDA for the period ended March 31, 2021, has been adjusted to reflect this current definition. Additionally, certain reclassifications have been made to Adjusted EBITDA for prior periods to conform to the current period presentation.

Trulieve reports Adjusted EBITDA to help investors assess the operating performance of the Company’s business. The financial measures noted above are metrics that have been adjusted from the GAAP net income measure in an effort to provide readers with a normalized metric in making comparisons more meaningful across the cannabis industry, as well as to remove non-recurring, irregular and one-time items that may otherwise distort the GAAP net income measure.

Adjusted EBITDA for the Three months ended March 31, 2022 was $105.5 million, an increase of $14.7 million from $90.8 million for the three months ended March 31, 2021. The following table presents a reconciliation of GAAP net income to non-GAAP Adjusted EBITDA, for each of the periods presented:

There have been no material changes to our market risk disclosures as set forth in Part II Item 7A of our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021.

~~a. Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures.~~

Our management, with the participation of the principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this quarterly report. Our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2021, we did not maintain effective disclosure controls and procedures because of the material weakness in internal control over financial reporting described below.

Notwithstanding the material weakness described below, we have concluded that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with U.S. GAAP.

We maintain disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the specified time periods and accumulated and communicated to our management, including our principal executive officer and principal accounting officer, as appropriate to allow timely decisions regarding disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the risk related to controls and procedures.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

~~As disclosed~~Management of the Company, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of its disclosure controls and procedures (as defined in "~~Note 2. Basis~~Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of ~~Presentation" under "Revisions~~1934, as amended (the “Exchange Act”) as of ~~Previously Issued~~March 31, 2022. Our Chief Executive Officer and Chief Financial Statements" during the quarter ended September 30, 2021, management identified errors in the accounting for leases, asset acquisitions, and classification of assets. Management reviewed these errors identifying the root causeOfficer have concluded that, due to the ~~control environment component~~material weaknesses identified in the prior period which are currently in the process of being remediated, as of March 31, 2022, we did not maintain effective disclosure controls and procedures because of the material weaknesses in internal control as described in Item 9A. Controls and Procedures in the ~~Company did not maintain a sufficient complement of personnel~~2021 Annual Report on Form 10-K, filed with the appropriate level of knowledge, experience, and training in certain areas important to financial reporting. During 2021, even though a material misstatement was not identified in the Company’s financial statements, it was determined that there was a reasonable possibility that a material misstatement in the Company’s financial statements would not have been prevented or detectedSEC on ~~a timely basis.~~March 30, 2022.

35Notwithstanding the material weaknesses described in the 2021 Annual Report on Form 10-K, we have concluded that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with U.S. GAAP.

Management is committed to maintaining a strong internal control environment. In response to the identified material ~~weakness~~weaknesses in the overall control environment, management, with the oversight of the Audit Committee of the Board of Directors, has taken actions toward the remediation of the respective material weakness in internal control over financial reporting as outlined below.

~~Initial remediation efforts have~~While significant progress has been ~~executed by the CAO, Director of Financial Reporting, and Assistant Controller with the implementation of control enhancements over internal controls over financial reporting.~~

~~These enhancements are targeted at strengthening the Company’s~~made to enhance our internal control over financial reporting, and remediating the material weakness. We remain committed to an effective internal control environment and management believes that these actions and the improvements management expects to achieve as a result, will effectively remediate the material weakness. However, the material weaknesses in the Company’s internal control over financial reporting will not be considered remediated until the controls operate for a sufficient period of time and management has concluded, through testing that these controls operate effectively. As of the date of filing this Form 10-Q, management iswe are still in the process of ~~testing~~building and ~~evaluating these additional controls~~enhancing our processes, procedures, and controls. Additional time is required to ~~determine whether they are operating effectively.~~complete the remediation of the material

weaknesses and the assessment to ensure the sustainability of these remediation actions. We believe the above actions as well as those being implemented currently, when complete, will be effective in the remediation of the material weaknesses described above.

~~Except for the material weakness and the remediation efforts described above,~~There have been no ~~other change~~changes in ~~our~~ internal ~~control~~controls over financial reporting ~~(as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred~~ during the ~~quarter under review,~~ three months ended March 31, 2022, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. Management believes these actions will help remediate internal control deficiencies related to the Company’s financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act).

36This Quarterly Report on Form 10-Q contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words. Any statements contained in this Quarterly Report on Form 10-Q that are not statements of historical facts may be deemed to be forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, results of operations and future growth prospects. The forward-looking statements contained herein are based on certain key expectations and assumptions, including, but not limited to, with respect to expectations and assumptions concerning receipt and/or maintenance of required licenses and third party consents and the success of our operations, are based on estimates prepared by us using data from publicly available governmental sources, as well as from market research and industry analysis, and on assumptions based on data and knowledge of this industry that we believe to be reasonable. These forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and discussed elsewhere in this Quarterly Report on Form 10-Q and in “Part I, Item 1A – Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this Quarterly Report on Form 10-Q. These factors and risks include, among other things, the following:

There are no actual or to our knowledge contemplated legal proceedings material to us or to which any of our or any of our subsidiaries’ property is the subject matter.

~~On December 30, 2019, a securities class-action complaint,~~ ~~David McNear v. Trulieve Cannabis Corp. et al., Case No. 1:19-cv-07289, was filed against us in the United States District Court for the Eastern District of New York. On February 12, 2020, a second securities class-action complaint,~~ ~~Monica Acerra v. Trulieve Cannabis Corp. et al.~~, Case No. 1:20-cv-00775, which is substantially similar to the complaint filed on December 30, 2019, was filed against us in the United States District Court for the Eastern District of New York. Both complaints name Trulieve, Kim Rivers, and Mohan Srinivasan as defendants for allegedly making materially false and misleading statements regarding our previously reported financial statements and public statements about our business, operations, and prospects. The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder. The complaints sought unspecified damages, costs, attorneys’ fees, and equitable relief. On March 20, 2020, the Court consolidated the two related actions under ~~In re Trulieve Cannabis Corp. Securities Litigation~~, No. 1:19-cv-07289, and appointed William Kurek, John Colomara, David McNear, and Monica Acerra as Lead Plaintiffs. The Company believes that the suit is immaterial and that the claims are without merit and intends to vigorously defend against them.

Investing in our Subordinate Voting Shares involves a high degree of risk. Our Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021 includes a detailed discussion of our risk factors under the heading “Part I, Item 1A—Risk Factors.” ~~Except as set forth below, there~~There have been no material changes from such risk factors during the quarter ended ~~September 30, 2021.~~March 31, 2022. You should consider carefully the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021 and all other information contained in or incorporated by reference in this Quarterly Report on Form 10-Q before making an investment decision. If any of the risks discussed in the Annual Report on Form 10-K for the year ended December 31, ~~2020 or herein~~2021 actually occur, they may materially harm our business, financial condition, operating results, cash flows or growth prospects. As a result, the market price of our Subordinate Voting Shares could decline, and you could lose all or part of your investment. Additional risks and uncertainties that are not yet identified or that we think are immaterial may also materially harm our business, financial condition, operating results, cash flows or growth prospects and could result in a complete loss of your investment.

We have identified a material weakness in our internal control over financial reporting, and our management has concluded that our disclosure controls and procedures are not effective. While we are working to remediate any material weakness or significant deficiencies in our internal controls over financial reporting, we cannot assure you that additional material weaknesses or significant deficiencies will not occur in the future. If our internal control over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results or prevent fraud, which may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price.

We have historically had a small internal accounting and finance staff. This lack of adequate accounting resources has resulted in the identification of a material weakness in our internal controls over financial reporting. A “material weakness” is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.

As disclosed in this Form 10-Q for the quarter ended September 30, 2021, our management team identified errors in the accounting for leases and asset acquisitions. Management reviewed these errors identifying the root cause due to the control environment component of internal control as the Company did not maintain a sufficient complement of personnel with the appropriate level of knowledge, experience, and training in certain areas important to financial reporting. During 2021, even though a material misstatement was not identified in the Company’s financial statements, it was determined that there was a reasonable possibility that a material misstatement in the Company’s financial statements would not have been prevented or detected on a timely basis.

We have taken actions toward the remediation of the material weakness in our internal control over financial reporting including: adding additional positions including Chief Accounting Officer, Director of Financial Reporting, Assistant Controller, Director of Shared Services, Northeast Controller, and Tax Director to provide enhanced oversight and technical experience in certain areas important to financial reporting; engaging third party experts to assist management in assessing current processes and designing improved processes and controls for the consolidated Company; adding a Chief Technology Officer to enhance the information technology environment

including automation of processes and controls and finalization of an ongoing SAP implementation; and reviewing business processes surrounding leases, acquisitions, and other complex financial reporting areas to identify and being the implementation of enhanced procedures related to internal controls. Nonetheless, the material weaknesses in the Company’s internal control over financial reporting will not be considered remediated until the controls operate for a sufficient period of time and management has concluded, through testing that these controls operate effectively. As of the date of this quarterly report, management is in the process of testing and evaluating these additional controls to determine whether they are operating effectively. We plan to continue to take additional steps to remediate the material weakness and improve our financial reporting systems and implement new policies, procedures and controls. If we do not successfully remediate the material weakness described above, or if other material weaknesses or other deficiencies arise in the future, we may be unable to accurately report our financial results, which could cause our financial results to be materially misstated and require restatement.

Trulieve and Harvest intend to integrate their operations. However, operational and strategic decisions and staffing decisions are ongoing. The closing of the acquisition presents challenges to management, including the integration of management structures, operations, information technology and accounting systems and personnel of the two companies, and special risks, including possible unanticipated liabilities, unanticipated costs, diversion of management’s attention and the loss of key employees or customers. The ability to realize the benefits of the Harvest acquisition may depend in part on successfully consolidating functions and integrating operations, procedures and personnel in a timely and efficient manner, as well as on Trulieve’s ability to realize the anticipated growth opportunities and synergies, efficiencies and cost savings from integrating Trulieve’s and Harvest’s businesses. The performance of the combined company could be adversely affected if the combined company cannot retain key employees to assist in the ongoing operations. As a result of these factors, it is possible that the cost reductions and synergies expected will not be realized. The difficulties that management encounters in the transition and integration processes could have an adverse effect on the revenues, level of expenses and operating results of the combined company. The amount and timing of the synergies the parties hope to realize may not occur as planned. As a result of these factors, it is possible that any anticipated benefits from the Harvest acquisition will not be realized.

~~Other than publicly-available information, Trulieve has relied on information made available by Harvest.~~

Other than publicly-available information, all historical information relating to Harvest in our public filings to date has been provided in exclusive reliance on the information made available by Harvest and its representatives. Although Trulieve has no reason to doubt the accuracy or completeness of the information provided by Harvest, any inaccuracy or omission in such information contained in our public filings could result in unanticipated liabilities or expenses, increase the cost of integrating Harvest into Trulieve’s existing business or adversely affect the operational plans of Trulieve and its result of operations and financial condition and may negatively affect the price of Trulieve’ Subordinate Voting Shares.

Disparate state-by-state regulatory landscapes and the constraints related to holding cannabis licenses in various states results in operational and legal structures for realizing the benefit from cannabis licenses that could result in materially detrimental consequences to us.

We realize, and will continue to realize, the benefits from cannabis licenses pursuant to a number of different structures, depending on the regulatory requirements from state-to-state, including, following the Harvest acquisition, realizing the economic benefit of cannabis licenses through management agreements and other commercial arrangements. Such agreements are often required to comply with applicable laws and regulations or are in response to perceived risks that we determine warrant such arrangements.

The foregoing structures present various risks to us and our subsidiaries including, but not limited to, the following risks, each of which could have a material adverse effect on our business, financial condition and results of operations:

~~In any or all of the above situations, it would be difficult and expensive for us to protect our rights through litigation, arbitration, or similar proceedings.~~

We operate in a highly regulated sector and may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where we carry on business including the jurisdictions in which Harvest, our newly acquired subsidiary, does business.

Our business and activities are heavily regulated in all jurisdictions where we carry on business. Our operations are subject to various laws, regulations and guidelines by state and local governmental authorities relating to the manufacture, marketing, management, transportation, storage, sale, pricing and disposal of cannabis and cannabis oil, and also including laws and regulations relating to health and safety, insurance coverage, the conduct of operations and the protection of the environment. Laws and regulations, applied generally, grant government agencies and self-regulatory bodies broad administrative discretion over our activities, including the power to limit or restrict business activities as well as impose additional disclosure requirements on our products and services. Achievement of our business objectives is contingent, in part, upon compliance with regulatory requirements enacted by these governmental authorities and obtaining all necessary regulatory approvals for the manufacture, production, storage, transportation, sale, import and export, as applicable, of our products. The commercial cannabis industry is still a new industry at the state and local level. The effect of relevant governmental authorities’ administration, application and enforcement of their respective regulatory regimes and delays in obtaining, or failure to obtain, applicable regulatory approvals which may be required may significantly delay or impact the development of markets, products and sales initiatives and could have a material adverse effect on our business, prospects, revenue, results of operation and financial condition.

While we endeavor to comply with all relevant laws, regulations and guidelines and, to our knowledge, we are in compliance or are in the process of being assessed for compliance with all such laws, regulations and guidelines, any failure to comply with the regulatory requirements applicable to our operations may lead to possible sanctions including the revocation or imposition of additional conditions on licenses to operate our business; the suspension or expulsion from a particular market or jurisdiction or of our key personnel; the imposition of additional or more stringent inspection, testing and reporting requirements; and the imposition of fines and censures. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to our operations, increase compliance costs or give rise to material liabilities and/or revocation of our licenses and other permits, which could have a material adverse effect on our business, results of operations and financial condition. Furthermore, governmental authorities may change their administration, application or enforcement procedures at any time, which may adversely impact our ongoing costs relating to regulatory compliance.

~~We may be subject to constraints on and differences in marketing our products under varying state laws, including the laws of the states in which Harvest, our recently acquired subsidiary operates.~~

There may be restrictions on sales and marketing activities imposed by government regulatory bodies that could hinder the development of our business and operating results. Restrictions may include regulations that specify what, where and to whom product information and descriptions may appear and/or be advertised. Marketing, advertising, packaging and labeling regulations also vary from state to state, potentially limiting the consistency and scale of consumer branding communication and product education efforts. The regulatory environment in the U.S. limits our ability to compete for market share in a manner similar to other industries. If we are unable to effectively market our products and compete for market share, or if the costs of compliance with government legislation and regulation cannot be absorbed through increased selling prices for our products, our sales and operating results could be adversely affected.

~~Our subsidiaries, including Harvest, may not be able to obtain or maintain necessary permits and authorizations.~~

Our subsidiaries may not be able to obtain or maintain the necessary licenses, permits, certificates, authorizations or accreditations to operate their respective businesses, or may only be able to do so at great cost. In addition, our subsidiaries may not be able to comply fully with the wide variety of laws and regulations applicable to the cannabis industry. Failure to comply with or to obtain the necessary licenses, permits, certificates, authorizations or accreditations could result in restrictions on a subsidiary’s ability to operate in the cannabis industry, which could have a material adverse effect on our business, financial condition or results of operations.

We face exposure to fraudulent or illegal activity by employees, contractors, consultants and agents, including the employees, contractors, consultants and agents of Harvest, our recently acquired subsidiary, which may subject us to investigations and actions.

We will be exposed to the risk that any of their employees, independent contractors and consultants may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates, (i) government regulations, (ii) manufacturing standards, (iii) federal and provincial healthcare fraud and abuse laws and regulations, or (iv) laws that require the true, complete and accurate reporting of financial information or data. It may not always be possible for us to identify and deter misconduct by our employees and other third parties, and the precautions taken by us to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. We cannot provide assurance that our internal controls and compliance systems will protect us from acts committed by our employees, agents or business partners in violation of U.S. federal or state or local laws. If any such actions are instituted against us, and we are not successful in defending or asserting our rights, those actions could have a material impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could have a material adverse effect on our business, financial condition or results of operations.

We may encounter increasingly strict environmental regulation in connection with our operations and the associated permitting, which may increase the expenses for cannabis production or subject us to enforcement actions by regulatory authorities.

Our operations are subject to environmental regulation in the various jurisdictions in which they operate. These regulations mandate, among other things, the maintenance of air and water quality standards and land reclamation. They also set forth limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Environmental legislation is evolving in a manner which will require stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors and employees. There is no assurance that future changes in environmental regulation, if any, will not have a material adverse effect on our business, financial condition or results of operations.

Government approvals and permits are currently, and may in the future be, required in connection with our operations. To the extent such approvals are required and not obtained, we may be curtailed or prohibited from our proposed production of cannabis or from proceeding with the development of our operations as currently proposed.

Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The subsidiaries may be required to compensate those suffering loss or damage by reason of their operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations.

Amendments to current laws, regulations and permits governing the production of cannabis, or more stringent implementation thereof, could cause increases in expenses, capital expenditures or production costs or reduction in levels of production or require abandonment or delays in development, and could have a material adverse effect on our business, financial condition or results of operations.

We may be required to disclose personal information to government or regulatory entities in the jurisdictions in which we do business, including the government and regulatory agencies in the jurisdictions in which Harvest, our recently acquired subsidiary, does business.

We own, manage, or provide services to various U.S. state licensed cannabis operations. Acquiring even a minimal and/or indirect interest in a U.S. state-licensed cannabis business can trigger requirements to disclose investors’ personal information. While these requirements vary by jurisdiction, some require interest holders to apply for regulatory approval and to provide tax returns, compensation agreements, fingerprints for background checks, criminal history records and other documents and information. Some states require disclosures of directors, officers and holders of more than a certain percentage of equity of the applicant. While certain states include exceptions for investments in publicly traded entities, not all states do so, and some such exceptions are confined to companies traded on a U.S. securities exchange. If these regulations were to extend to us, investors would be required to comply with such regulations, or face the possibility that the relevant cannabis license could be revoked or cancelled by the state licensing authority.

~~Furnish the exhibits required by Item 601 of Regulation S-K (§ 229.601 of this chapter).~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


British Columbia	84-2231905
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

6749 Ben Bostic Road Quincy, FL	32351
(Address of principal executive offices)	(Zip Code)


		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021	1
	Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the three months ended March 31, 2022 and 2021	2
	Condensed Consolidated Statements of Changes in Shareholders’ Equity for the three months ended March 31, 2022 and 2021	3
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021	54
	Notes to ~~Unaudited~~ Condensed Consolidated Financial Statements	65
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2535
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3544
Item 4.	Controls and Procedures	3544

PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	3747
Item 1A.	Risk Factors	3747
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4147
Item 3.	Defaults Upon Senior Securities	4147
Item 4.	Mine Safety Disclosures	4147
Item 5.	Other Information	4147
Item 6.	Exhibits	4248
	Signatures	4349


					March 31, 2022		December 31, 2021
	September 30, 2021		December 31, 2020		(unaudited)		(audited)
ASSETS
Current assets:
Cash and cash equivalents	$	213,574	$	146,713	$	267,226	$	230,646
Restricted cash						—		3,013
Accounts receivable, net		8,487		308		12,782		8,854
Inventories, net		133,874		98,312		236,427		212,188
Income tax receivable, net		3,978		—
Notes receivable - current portion						634		1,530
Prepaid expenses and other current assets		25,791		16,119		76,182		68,189
Total current assets		385,704		261,452		593,251		524,420
Property and equipment, net		501,109		314,045		805,999		779,916
Right of use assets - operating, net		45,753		30,076		121,972		125,973
Right of use assets - finance, net		58,393		36,904		70,225		66,764
Intangible assets, net		161,282		93,800		1,098,278		1,117,982
Goodwill		111,721		74,100		789,900		765,358
Notes receivable, net						12,188		12,147
Other assets		12,077		7,528		34,041		18,312
TOTAL ASSETS	$	1,276,039	$	817,905	$	3,525,854	$	3,410,872
LIABILITIES AND SHAREHOLDERS' EQUITY
LIABILITIES
Current liabilities:
Accounts payable and accrued liabilities	$	62,769	$	41,903		109,810		94,073
Income tax payable	��	—		5,875		77,687		27,610
Deferred revenue		4,082		7,178		6,514		7,168
Notes payable - current portion		6,000		2,000
Notes payable - related party - current portion		12,000		12,011
Notes payable - current portion, net						9,481		10,052
Private placement notes - current portion						1,874		—
Operating lease liabilities - current portion		4,264		3,277		10,553		9,840
Finance lease liabilities - current portion		5,354		3,877		6,905		6,185
Construction finance liabilities - current portion						1,154		991
Contingencies						13,826		13,017
Total current liabilities		94,469		76,121		237,804		168,936
Long-term liabilities:
Notes payable		—		4,000		3,476		6,456
Private placement notes, net						537,703		462,929
Warrant liabilities						2,075		2,895
Operating lease liabilities		43,657		28,120		128,575		122,130
Finance lease liabilities		57,234		35,058		69,167		65,244
Private placement notes liabilities, net		119,478		117,165
Construction finance liabilities						175,032		175,198
Deferred tax liabilities						243,395		251,311
Other long-term liabilities		6,438		3,915		9,433		8,400
Construction finance liabilities		92,021		82,047
Deferred tax liability		40,099		23,575
TOTAL LIABILITIES		453,396		370,001		1,406,660		1,263,499

Commitments and contingencies (see Note 17)

Common stock, no par value; unlimited shares authorized, 129,531,207 and 119,573,998 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively		—		—
Commitments and contingencies (see Note 21)
SHAREHOLDERS' EQUITY
Common stock, no par value; unlimited shares authorized. 184,184,142 issued and outstanding as of March 31, 2022 and 180,504,172 issued and outstanding as of December 31, 2021.						—		—
Additional paid-in-capital		613,379		328,214		2,012,564		2,008,100
Accumulated earnings		209,264		119,690		105,746		137,721
Non-controlling interest						884		1,552
TOTAL SHAREHOLDERS' EQUITY		822,643		447,904		2,119,194		2,147,373
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	1,276,039	$	817,905	$	3,525,854	$	3,410,872


													Three Months Ended
	Three Months Ended						Nine Months Ended						March 31, 2022			March 31, 2021
	September 30, 2021			September 30, 2020			September 30, 2021			September 30, 2020			(unaudited)
Revenues, net of discounts	$	224,092		$	136,274		$	633,037		$	353,096		$	318,348		$	193,823
Cost of goods sold		70,147			34,097			199,345			86,557			140,198			58,559
Gross profit		153,945			102,177			433,692			266,539			178,150			135,264
Expenses:
Sales and marketing		51,724			30,890			142,858			80,764			72,862			44,558
General and administrative		28,218			8,502			55,869			22,696			33,546			12,709
Depreciation and amortization		7,728			3,314			19,829			8,612			29,305			5,434
Impairment and disposal of long-lived assets														13,780			—
Total expenses		87,670			42,706			218,556			112,072			149,493			62,701
Income from operations		66,275			59,471			215,136			154,467			28,657			72,563
Other income (expense):
Interest expense, net		(6,145	)		(5,352	)		(20,693	)		(16,566	)		(17,877	)		(7,899	)
Other (expense) income, net		89			(10,756	)		385			(10,827	)
Change in fair value of derivative liabilities - warrants														820			—
Loss on divestment and sale of non-operating assets														(2,681	)		—
Other income (expense), net														915			(37	)
Total other expense		(6,056	)		(16,108	)		(20,308	)		(27,393	)		(18,823	)		(7,936	)
Income before provision for income taxes		60,219			43,363			194,828			127,074			9,834			64,627
Provision for income taxes		41,603			25,948			105,254			67,116			42,316			34,549
Net income and comprehensive income		18,616			17,415			89,574			59,958
Basic net income per common share	$	0.15		$	0.16		$	0.73		$	0.54
Diluted net income per common share	$	0.14		$	0.15		$	0.68		$	0.52
Weighted average number of common shares used in computing net income per common share:
Net (loss) income and comprehensive (loss) income														(32,482	)		30,078
Less: Net loss and comprehensive loss attributed to non-controlling interest														(507	)		—
Net (loss) income and comprehensive (loss) income attributed to common shareholders													$	(31,975	)	$	30,078

Net (loss) income per share:
Basic		128,146,298			112,039,640			122,983,729			111,824,816		$	(0.17	)	$	0.25
Diluted		136,909,266			117,949,224			130,927,083			115,998,704		$	(0.17	)	$	0.24
Weighted average number of common shares used in computing net (loss) income per common share:
Basic														187,054,916			119,892,507
Diluted														187,054,916			127,589,096


	Super Voting Shares			Multiple Voting Shares			Subordinate Voting Shares		Total Common Shares		Additional Paid-in-Capital		Accumulated Earnings		Total
Balance, January 1, 2020		67,813,300			6,661,374			35,871,672		110,346,346	$	76,192	$	56,691	$	132,883
Share-based compensation		—			—			—		—		1,222		—		1,222
Net income and comprehensive income		—			—			—		—		—		23,605		23,605
Balance, March 31, 2020		67,813,300			6,661,374			35,871,672		110,346,346	$	77,414	$	80,296	$	157,710
Share-based compensation		—			—			—		—		462		—		462
Shares issued for cash - warrant exercise		—			—			2,723,311		2,723,311		11,458		—		11,458
Net income and comprehensive income		—			—			—		—		—		18,938		18,938
Balance, June 30, 2020		67,813,300			6,661,374			38,594,983		113,069,657	$	89,334	$	99,234	$	188,568
Share-based compensation		—			—			—		—		523		—		523
Shares issued for cash - warrant exercise		—			—			100		100		1		—		1
Exercise of Stock Options		—			—			9,180		9,180		—		—		—
Issuance of shares private placement, net of issuance costs		—			—			4,715,000		4,715,000		83,228		—		83,228
Conversion of Super Voting Shares to Subordinate Voting Shares		(9,630,800	)		—			9,630,800		—		—		—		—
Conversion of Multiple Voting Shares to Subordinate Voting Shares		—			(5,184,415	)		5,184,415		—		—		—		—
Net income and comprehensive income		—			—			—		—		—		17,415		17,415
Balance, September 30, 2020		58,182,500			1,476,959			58,134,478		117,793,937	$	173,086	$	116,649	$	289,735


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


	Three Months Ended March 31, 2022			Three Months Ended March 31, 2021
	(unaudited)
Cash flow from operating activities
Net (loss) income and comprehensive (loss) income	$	(32,482	)	$	30,078
Adjustments to reconcile net (loss) income and comprehensive (loss) income to net cash provided by operating activities:
Depreciation and amortization		29,305			5,434
Depreciation included in cost of goods sold		10,692			3,667
Non-cash interest expense		1,232			(41	)
Non-cash interest income		(163	)		—
Loss on impairment and disposal of long-lived assets		13,780			—
Loss on settlement of held for sale assets, net		1,862			—
Loss on lease terminations		819			—
Amortization of operating lease right of use assets		2,892			1,573
Share-based compensation		4,564			741
Accretion of construction finance liabilities		293			711
Change in fair value of derivative liabilities - warrants		(820	)		—
Change in legal contingencies		(1,248	)		—
Allowance for credit losses		42			—
Deferred income tax expense		—			(1,487	)
Changes in operating assets and liabilities:
Inventories		(21,957	)		(5,598	)
Accounts receivable		(3,970	)		(2,309	)
Prepaid expenses and other current assets		(8,094	)		(1,673	)
Other assets		(16,216	)		(7,298	)
Accounts payable and accrued liabilities		22,093			595
Income tax payable		42,210			36,540
Operating lease liabilities		(2,106	)		(943	)
Deferred revenue		(654	)		(399	)
Other current liabilities		2,057			—
Other long-term liabilities		1,016			—
Net cash provided by operating activities		45,147			59,591
Cash flow from investing activities
Purchases of property and equipment		(48,118	)		(48,387	)
Purchases of property and equipment related to construction finance liabilities		(7,334	)		(3,687	)
Capitalized interest		(1,487	)		(365	)
Acquisitions, net of cash acquired		(27,500	)		91
Purchases of internal use software		(2,214	)		(1,014	)
Proceeds from sale of variable interest entity		1,604			—
Proceeds from sale of held for sale assets		203			—
Proceeds received from notes receivable		1,018			—
Net cash used in investing activities		(83,828	)		(53,362	)
Cash flow from financing activities
Proceeds from private placement notes, net of discounts		76,420			—
Proceeds from construction finance liabilities		—			3,687
Proceeds from warrant exercises		22			6,861
Proceeds from stock option exercises		108			—
Payments on notes payable		(2,285	)		—
Payments on finance lease obligations		(1,421	)		(1,028	)
Payments on construction finance liabilities		(297	)		—
Payments for debt issuance costs		(19	)		—
Payments on notes payable - related party		—			(12	)
Payments for taxes related to net share settlement of equity awards		(230	)		—
Distributions		(50	)		—
Net cash provided by financing activities		72,248			9,508
Net increase in cash and cash equivalents		33,567			15,737
Cash, cash equivalents, and restricted cash, beginning of period		233,659			146,713
Cash, cash equivalents, and restricted cash, end of period	$	267,226		$	162,450
Supplemental disclosure of cash flow information
Cash paid during the period for
Interest	$	6,949		$	540
Income taxes	$	46		$	—
Other noncash investing and financing activities
ASC 842 lease additions - operating and finance leases	$	10,852		$	10,697
Purchases of property and equipment financed with accounts payable	$	10,985		$	13,155


	Nine Months Ended September 30, 2021			Nine Months Ended September 30, 2020
Cash flow from operating activities
Net income and comprehensive income	$	89,574		$	59,958
Adjustments to reconcile net income and comprehensive income to net cash provided by operating activities:
Depreciation and amortization		19,829			8,612
Depreciation included in cost of goods sold		14,396			7,424
Non-cash interest expense		2,313			2,142
(Gain) loss from sale of property and equipment		(5	)		63
Amortization of operating lease right of use assets		3,216			2,383
Share-based compensation		2,217			2,208
Accretion of construction finance liabilities		1,097			617
Loss on fair value of warrants		—			12,782
Deferred income tax expense		(2,111	)		(2,324	)
Changes in operating assets and liabilities:
Inventories		(33,796	)		(11,687	)
Accounts receivable		(8,179	)		—
Prepaid expenses and other current assets		(9,412	)		(6,915	)
Other assets		(4,509	)		(5,790	)
Income tax payable / receivable		(12,745	)		1,911
Accounts payable and accrued liabilities		17,853			1,303
Operating lease liabilities		(1,906	)		(2,054	)
Deferred revenue		(3,096	)		2,207
Other long-term liabilities		344			—
Net cash provided by operating activities		75,080			72,840
Cash flow from investing activities
Purchases of property and equipment		(190,907	)		(61,359	)
Purchases of property and equipment related to construction finance liabilities		(8,877	)		(27,381	)
Cash paid for internal use software		(3,587	)		—
Acquisitions, net of cash acquired		(29,924	)		—
Proceeds from sale of property and equipment		8			16
Capitalized interest		(4,355	)		(2,090	)
Net cash used in investing activities		(237,642	)		(90,814	)
Cash flow from financing activities
Proceeds from share warrant exercises		7,672			11,459
Proceeds from construction finance liabilities		8,877			28,582
Proceeds from shares issued pursuant to private placement		217,896			83,228
Payments on finance lease obligations		(4,024	)		(2,824	)
Payments on notes payable - related party		(11	)		(907	)
Payments for taxes related to net share settlement of equity awards		(987	)		—
Net cash provided by financing activities		229,423			119,538
Net increase in cash and cash equivalents		66,861			101,564
Cash and cash equivalents, beginning of period		146,713			91,813
Cash and cash equivalents, end of period	$	213,574		$	193,377
Supplemental disclosure of cash flow information
Cash paid during the period for
Interest	$	22,653		$	12,798
Income taxes	$	120,365		$	70,996
Other noncash investing and financing activities
Adjustment to PurePenn, LLC and Solevo contingent consideration	$	2,800		$	—
ASC 842 lease additions - operating and finance leases	$	43,748		$	23,096
Shares issued for acquisitions	$	57,452		$	—
Purchase of property and equipment financed with accounts payable	$	16,148		$	7,167


Balance Sheet as of June 30, 2021 (unaudited)	As Previously Reported		Adjustment			As Revised
Prepaid expenses and other current assets	$	28,313	$	(4,249	)	$	24,064
Total current assets		442,090		(4,249	)		437,841
Property and equipment, net		427,666		258			427,924
Right of use assets - operating, net		31,254		8,768			40,022
Right of use assets - finance, net		41,521		6,371			47,892
Intangible assets, net		123,106		(621	)		122,485
Other assets		9,547		4,246			13,793
Total assets		1,146,307		14,773			1,161,080
Operating lease liabilities, current portion		3,583		432			4,015
Finance lease liabilities, current portion		4,723		281			5,004
Total current liabilities		76,738		713			77,451
Operating lease liabilities		29,381		8,396			37,777
Finance lease liabilities		39,694		5,822			45,516
Deferred tax liability		29,845		(2,213	)		27,632
Total liabilities		390,072		12,718			402,790
Additional paid-in-capital		522,898		2,055			524,953
Total shareholders equity	$	756,235	$	2,055		$	758,290


Balance Sheet as of December 31, 2020	As Previously Reported		Adjustment			As Revised
Prepaid expenses and other current assets	$	19,815	$	(3,696	)	$	16,119
Total current assets		265,148		(3,696	)		261,452
Right of use assets - operating, net		28,171		1,905			30,076
Other assets		3,944		3,584			7,528
Total assets		816,112		1,793			817,905
Operating lease liabilities, current portion		3,154		123			3,277
Total current liabilities		75,998		123			76,121
Operating lease liabilities		26,450		1,670			28,120
Total liabilities	$	368,208	$	1,793		$	370,001


	September 30, 2021
(dollars in thousands)	Net amount		Adjustments to purchase price allocation		Additions		Amortization expense			Net amount
Licenses	$	84,517	$	3,061	$	68,493	$	(5,593	)	$	150,478
Internal use software		3,656		—		3,589		(529	)		6,716
Moxie brand		2,828		—		—		(740	)		2,088
Tradenames		2,109		—		100		(741	)		1,468
Customer relationship		683		—		—		(151	)		532
Miscellaneous		7		—		86		(93	)		—
	$	93,800	$	3,061	$	72,268	$	(7,847	)	$	161,282


	December 31, 2020
(dollars in thousands)	Net amount		Acquired license agreements		Additions		Amortization expense			Net amount
Licenses	$	24,538	$	887	$	61,400	$	(2,308	)	$	84,517
Internal use software		3,656		—		—		—			3,656
Moxie brand		—		—		2,960		(132	)		2,828
Tradenames		800		—		1,510		(201	)		2,109
Customer relationship		883		—		—		(200	)		683
Miscellaneous		25		—		—		(18	)		7
Trademarks		134		—		—		(134	)		—
	$	30,036	$	887	$	65,870	$	(2,993	)	$	93,800


	Estimated amortization
	(dollars in thousands)
Remaining 2021	$	3,326
2022		13,887
2023		13,320
2024		12,349
2025		11,895
Thereafter		106,505
	$	161,282


(dollars in thousands)
At January 1, 2020		7,316
Acquisition of PurePenn, LLC and Pioneer Leasing & Consulting, LLC		47,311
Acquisition of Solevo Wellness		19,473
At December 31, 2020		74,100
Measurement period purchase price allocation adjustments of Solevo Wellness		(2,639	)
Measurement period purchase price allocation adjustments of PurePenn, LLC and Pioneer Leasing & Consulting, LLC		(338	)
At June 30, 2021		71,123
Acquisition of Keystone Shops		40,072
Measurement period purchase price allocation adjustments of Solevo Wellness		1,150
Measurement period purchase price allocation adjustments of PurePenn, LLC and Pioneer Leasing & Consulting, LLC		(624	)
At September 30, 2021	$	111,721


As of September 30,	(dollars in thousands)
2021	$	2,000
2022		4,000
	$	6,000


	Private placement notes
	(dollars in thousands)
2021	$	—
2022		—
2023		—
2024		130,000
2025		—
Thereafter		—
Total debt		130,000
Less: unamortized debt issuance costs		(10,522	)
Net debt	$	119,478


	Operating lease			Finance lease
Weighted average discount rate		8.75	%		8.46	%
Weighted average remaining lease term (in years)		8.67			8.20


	Number of Warrants		Weighted average exercise price ($CAD)		Weighted average remaining contractual life (Yrs)
Outstanding and exercisable as of December 31, 2020		—		—		—
Granted		1,679		1,125		1.31
Exercised		—
Outstanding and exercisable as of December 31, 2021		1,679		1,125		1.31
Granted		—		—		—
Exercised		—		—		—
Outstanding and exercisable as of March 31, 2022		1,679		1,125		1.31


	Number of restricted stock units			Weighted average grant price
Balance as of January 1, 2021		—			—
Granted		3,249,319			25.45
Vested		(2,904,079	)		25.28
Forfeited		—			—
Balance as of September 30, 2021		345,240		$	26.88


	For the Three Months Ended September 30,						For the Nine Months Ended September 30,						For the Three Months Ended March 31,
	2021			2020			2021			2020			2022			2021
	(dollars in thousands)						(dollars in thousands)						(in thousands)
Income before provision for income taxes	$	60,219		$	43,363		$	194,828		$	127,074		$	9,834		$	64,627
Provision for income taxes		41,603			25,948			105,254			67,116			42,316			34,549
Effective tax rate		69	%		60	%		54	%		53	%		430	%		53	%


	As of September 30, 2021				As of December 31, 2020				As of March 31, 2022		As of December 31, 2021
	Operating		Finance		Operating		Finance		Operating		Operating		Finance
	(dollars in thousands)				(dollars in thousands)				(in thousands)		(in thousands)
Right-of-use assets, net	$	6,116	$	2,080	$	12,003	$	3,425	$	899	$	2,082	$	2,009
Lease liabilities:
Lease liabilities - current portion		725		207		1,539		281	$	103	$	418	$	215
Lease liabilities		5,790		2,184		11,083		3,500		837		1,862		2,127
Total related parties lease liabilities	$	6,515	$	2,391	$	12,622	$	3,781	$	940	$	2,280	$	2,342


	Level 1		Level 2		Level 3		Total
	(in thousands)
Financial Assets:
Money market funds (1)	$	94,784	$	—	$	—	$	94,784
Financial Liabilities:
Warrant liabilities (2)	$	—	$	2,075	$	—	$	2,075


	Three Months Ended					Nine Months Ended
	September 30,				Change	September 30,				Change
	2021		2020		%	2021		2020		%
	(dollars in thousands)					(dollars in thousands)
Revenues, net of discounts	$	224,092	$	136,274	64%	$	633,037	$	353,096	79%


	Three Months Ended
	March 31,				Change
	2022		2021		%
	(in thousands)
Revenues, net of discounts	$	318,348	$	193,823	64%


	Three Months Ended September 30,					Nine Months Ended September 30,
	2021		2020		Change	2021		2020		Change
	(dollars in thousands)					(dollars in thousands)
Net income and comprehensive income	$	18,616	$	17,415	7%	$	89,574	$	59,958	49%


	Three Months Ended March 31,
	2022			2021		Change
	(in thousands)
Net (loss) income and comprehensive income	$	(32,482	)	$	30,078	-208%


	Three Months Ended September 30,					Nine Months Ended September 30,
	2021			2020		2021			2020
	(dollars in thousands)					(dollars in thousands)
Net income and comprehensive income	$	18,616		$	17,415	$	89,574		$	59,958
Add impact of:
Interest expense, net		6,145			5,352		20,693			16,566
Provision for income taxes		41,603			25,948		105,254			67,116
Depreciation and amortization		7,728			3,314		19,829			8,612
Depreciation included in cost of goods sold		5,709			2,533		14,396			7,424
EBITDA		79,801			54,562		249,746			159,676
Acquisition and transaction costs		11,114			—		14,335			—
COVID related expenses		503			2,883		6,014			5,957
Share-based compensation and related premiums		4,922			523		6,407			2,208
Inventory step up, fair value		710			—		3,238			—
Integration and transition costs		838			—		2,725			—
Other non-recurring costs		235			—		1,622			—
Other expense (income), net		(89	)		10,756		(385	)		10,827
Total adjustment		18,233			14,162		33,956			18,992
Adjusted EBITDA	$	98,034		$	68,724	$	283,702		$	178,668


	Nine Months Ended September 30,		Year Ended December 31,
	2021		2020
	(dollars in thousands)
Cash and cash equivalents	$	213,574	$	146,713
Outstanding debt:
Notes payable		6,000		6,000
Notes payable - related party		12,000		12,011
Private placement notes		130,000		130,000
Operating lease liability		47,921		31,397
Finance lease liability		62,588		38,935
Construction finance liability	$	92,021	$	82,047


	<1 Year		1 to 3 Years		3 to 5 Years		>5 Years		Total
	(dollars in thousands)
Accounts payable and accrued liabilities	$	62,769	$	—	$	—	$	—	$	62,769
Notes payable		6,000		—		—		—		6,000
Notes payable - related party		12,000		—		—		—		12,000
Private placement notes		—		—		130,000		—		130,000
Operating lease liability		1,991		16,059		15,559		35,893		69,502
Finance lease liability		2,494		23,755		18,464		43,875		88,588
Construction finance liability		12,300		38,963		27,792		164,432		243,487


Exhibit Number		Description

~~3.1~~4.1		~~Articles~~Trust Indenture, dated as of June 18, 2019, between Trulieve Cannabis Corp.~~, as amended~~ and Odyssey Trust Company (incorporated by reference to Exhibit ~~3.1~~4.7 to the Company’s Registration Statement on Form S-1 (File No. 333-252052) ~~filed with the SEC on January 12, 2021)~~)

~~4.1~~4.2		Supplemental Trust Indenture, dated as of October 6, 2021, ~~by and~~ between Trulieve Cannabis Corp. and Odyssey Trust Company (incorporated by reference to Exhibit 4.1 to the ~~Company's Current Report on Form 8-K (File No. 000-56248) filed with the SEC on October 8, 2021)~~

~~10.1~~		Restricted Share Unit Award Agreement dated as of September 15, 2021 by and between Trulieve Cannabis Corp. and Kim Rivers (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 000-56248) filed with the SEC on September 17, 2021)

~~10.2~~		Restricted Share Unit Award Agreement dated as of September 15, 2021 by and between Trulieve Cannabis Corp. and Jason Pernell (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K (File No. 000-56248) filed with the SEC on September 17, 2021)

~~10.3~~		Executive Employment Agreement dated September 29, 2021 by and between Trulieve Cannabis Corp. and Kim Rivers (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 000-56248) filed with the SEC on September 30, 2021)

~~10.4~~		~~Executive Employment Agreement dated September 29, 2021 by and between Trulieve Cannabis Corp. and Alex D’Amico (incorporated by reference to Exhibit 10.2 to the~~ Company’s Current Report on Form 8-K (File No. 000-56248) ~~filed with the SEC on September 30, 2021)~~)

~~10.5~~4.3		~~Executive Employment Agreement dated September 29, 2021 by and between Trulieve Cannabis Corp. and Eric Powers (incorporated by reference to~~Form of 2026 Note (included in Exhibit ~~10.3 to the Company’s Current Report on Form 8-K (File No. 000-56248) filed with the SEC on September 30, 2021)~~4.2)

~~10.6~~		Executive Employment Agreement dated September 29, 2021 by and between Trulieve Cannabis Corp. and Rebecca Young (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K (File No. 000-56248) filed with the SEC on September 30, 2021)

31.131.1		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of ~~2002.~~2002
31.2 *
31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of ~~2002.~~2002
32.1 *
32.1*		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of ~~2002.~~2002

101.INS*101.INS		Inline XBRL Instance Document
101.SCH*101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL*101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)


	TRULIEVE CANNABIS CORP.

Date: ~~November 15, 2021~~May 12, 2022	By:	/s/ Kim Rivers
		Kim Rivers
		Chief Executive Officer
		(Principal Executive Officer)

Date: ~~November 15, 2021~~May 12, 2022	By:	/s/ Alex D’Amico
		Alex D’Amico
		Chief Financial Officer
		(Principal Financial Officer)

Date: ~~November 15, 2021~~May 12, 2022	By:	/s/ Rebecca Young
		Rebecca Young Chief Accounting Officer
		(Principal Accounting Officer)

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company